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Non-alcoholic fatty liver disease (NAFLD) is a metabolic disease characterised by the 
accumulation of fat in the liver. It is estimated that 33 % of the UK population have 
NAFLD with 2-5 % progressing to non-alcoholic steatohepatitis (NASH). Due to a 
lack of an outright therapy for NAFLD, treatment has been mainly focussed on 
managing the conditions associated with the disease such as obesity, diabetes mellitus 
and hyperlipidaemia.  
 
This study aimed to investigate the means by which hepatocyte protection is conferred 
by Gentiana plants (Gentiana lutea, Gentiana macrophylla, Gentiana scabra and 
Gentiana rigescens) used in herbal medicine for the management of non-alcoholic 
fatty liver diseases (NAFLD). The role played by some of the inherent Gentiana 
phytochemicals including: gentiopicroside, sweroside and swertiamarin in promoting 
hepatocyte protection against the cytotoxic effects of fatty acids were also 
investigated. Gentiana species: lutea, macrophylla, rigescens, and scabra are known 
to protect and enhance hepatocyte viability via their antioxidant, anti-inflammatory 
and bitter components including: amarogentin gentianine, iso-orientin, swertiamarin, 
gentiopicroside, and sweroside. This study was necessitated due to a lack of adequate 
research on the hepatoprotective effects of the above-named Gentiana species and 
phytochemicals with special emphasis on their effect on mitochondrial respiration in 
the presence of fatty acids.  
 
At the time of submission, this was the first study to utilise the seahorse mitochondria 
stress assay to investigate the Gentiana species as well as phytochemicals: 
gentiopicroside, sweroside and swertiamarin. It was also found that the most abundant 
phytochemical in all four Gentiana species was gentiopicroside (up to 4.6% g/g), 
followed by swertiamarin (0.21–0.45% g/g), and sweroside (0.03- 0.4 % g/g).  
Furthermore, it was also observed that the methanolic extracts of all four Gentiana 
protected HepG2 and THLE-2 cells by inhibiting arachidonic acid from diminishing 
cell replication but showed a mitogenic effect mostly observed in gentiopicroside, 
Gentiana lutea and Gentiana macrophylla.  
 
It was concluded that phytochemicals: gentiopicroside, sweroside and swertiamarin 
play key roles in the hepatocyte protection exerted by methanolic extracts of Gentiana 
lutea, Gentiana macrophylla, Gentiana scabra and Gentiana rigescens against the 
cytotoxic effects of fatty acids.  This protection is conferred by enhancing 
mitochondrial function in terms of increasing maximal respiratory capacity in 
response to high influx of fatty acids, promoting ATP production as well as scavenging 
ROS produced as a result of high fatty acid influx and increased mitochondrial 
respiration. However, the mitogenic effect observed in gentiopicroside and Gentiana 
macrophylla requires further studies using unmodified primary hepatocytes to gain 
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1.0 Overview of Gentiana Species Profile, Phytochemicals and Utilisation 
The Gentiana genus which originates from the Gentianaceae family is composed of up 
to 300 different species of plants, some of which are: G. lutea, G. macrophylla, G. 
rigescens, G. crassicaulis G. dahurica, G. asclepiadea, G. manshurica, G. straminea, 
G. olivieri and G. scabra (Yang et al., 2010, Tang and Eisenbrand, 2011). The species 
of plants found in the Gentiana genus have been found to possess several 
pharmacological activities including being: hepatoprotective, anti-inflammatory, 
antioxidant and antihypertensive. These actions may be attributed to inherent 
phytochemicals such as iridoids, flavonoids, xanthones, triterpenoids and secoiridoid 
(Jensen and Schripsema, 2002, Chong, 2008). Over 90 iridoid compounds, up to 34 
flavonoids and 100 xanthones have been isolated from species of plants belonging to 
the Gentiana genus (Wang et al., 2009a). 
 
A typical example of pharmacological effects of plants in the Gentiana genus was 
observed in aerial parts of Gentiana olivieri which were administered subcutaneously 
to rats in assessing its effect on carbon tetrachloride induced hepatic damage. It was 
observed that Gentiana olivieri exerted anti-hepatotoxic effects via its phytochemical 
isoorientin (Orhan et al., 2003).  Methanolic extracts of Gentiana asclepiadea 
administered to Wistar rats exhibited hepatoprotective effects by significantly 
reducing the level of serum transaminases, alkaline phosphatase and total bilirubin in 
the presence of carbon tetrachloride. The extent of hepatoprotection conferred was 
comparable to silymarin which was used as a reference compound (Mihailovic et al., 
2013). Furthermore, anti-viral and anti-tumour effects of Gentiana asclepiadea have 
also been reported (Devic et al., 2006). Hepatoprotective effects of Gentiana 
manshurica were shown by suppressing the elevation of malondialdehyde, promoting 
superoxide dismutase and glutathione production after being administered to mice 
intoxicated with alcohol (Lian et al., 2010). According to the Chinese Materia Medica 
2-10 g decoction of the rhizomes of Gentiana manshurica or Gentiana scabra or 
Gentiana rigescens can be administered in the treatment of jaundice and also for the 
improvement of liver and gallbladder functions (Enquin, 1990). Table 1.1 provides a 
summary of pharmacological effects of Gentiana plants, parts used and 




Table 1.1 Summarised pharmacological effects of Some Gentiana plants. 
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The major secoiridoid glycoside found in the root and rhizome of Gentiana species is 
gentiopicroside whereas the minor entails amarogentin, sweroside amaroswerin and 
swertiamarin. It has been reported that in the Gentianaceae family which entails the 
Gentiana genus; sweroside, swertiamarin and gentiopicroside are the most commonly 
found phytochemicals with gentiopicroside and swertiamarin exclusively found in the 
Gentianaceae family (Jensen and Schripsema, 2002). It is estimated that the 
gentiopicroside content of Gentiana species after quantitation should not be less than 
1.0 % g/g (Tang and Eisenbrand, 2011). Gentiopicroside, which can be obtained from 
Gentiana macrophylla, Gentiana lutea, Gentiana rigescens as well as Gentiana 
scabra has been indicated as an anti-viral, hepatoprotective and anti-inflammatory 
agent (Wu et al., 2017, Tang et al., 2016). Gentiopicroside has been used to treat a 
number of inflammatory conditions such as liver disease (hepatitis), rheumatoid 
arthritis, fever, digestive and intestinal disorders (Kondo et al., 1994). Amarogentin 
which is a secoiridoid glycoside and the bitterest substance is used as an 
anticarcinogenic and antileishmanial agent. It inhibited the hyperproliferation of 
cancerous cells by downregulating cyclooxygenase (COX II) and upregulating 
apoptosis in a dermal carcinogenic model in mice. Amarogentin can be found in 
Gentiana lutea and Swertia chirata (Vanhaelen and Vanhaelen-Fastre, 1983, Saha et 
al., 2006). Norswertianolin which is a xanthone found in Gentiana campestris as well 
as Swertia davidi has been indicated as an acetylcholinesterase inhibitor (Zeng et al., 
2004, Urbain et al., 2004). Table 1.2 provides a summary of pharmacological effects 
of some Gentiana phytochemicals, their classification and plants from which they can 
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Sweroside which can be obtained from Gentiana lutea, Gentiana tibetica, Fructus 
corni, Gentiana macrophylla and Gentiana scabra showed hepatoprotective effects 
against lipopolysaccharide-induced liver injury in mice and has also been indicated as 
an antifungal agent  (Tan et al., 1998a, Ikeshiro and Tomita, 1983, Sun et al., 2013a).  
The administration of swertiamarin (100-200 mg/kg) body weight of rats significantly 
reduced liver injury and lipid peroxidation induced with d-galactosamine (Jaishree and 
Badami, 2010) Swertiamarin can be found in Gentiana macrophylla, Gentiana 
manshurica, Gentiana lutea, Gentiana scabra and Gentiana lutea (Liu et al., 1994, 
Öztürk et al., 2006, Wang et al., 2010b). Loganic acid presented an anti-inflammatory 
effect by inhibiting rat paw oedema induced with carrageenam by up to 44.4 % (del 
Carmen Recio et al., 1994). It can be isolated from Gentiana manshurica, Gentiana 
lutea  (Aberham et al., 2007, Lin et al., 2004). Research by (Niiho et al., 2006) 
indicated that amaroswerin derived from Gentiana lutea prevented ethanol-induced 
gastritis in rats. Other sources of amaroswerin include Swertia japonica, Gentiana 
manshurica, Gentiana purpurea and Gentiana punctata (Quercia et al., 1980, 




From the above, it could be deduced that Gentiana plants and their phytochemicals 
have variable pharmacological effects and applications. In this study however, the 
main point of focus was their hepatoprotective effects in terms of non-alcoholic fatty 
liver disease (NAFLD).   
1.1. Non-alcoholic fatty liver disease (NAFLD) 
The liver serves as a key determinant of the health status of an individual and hence 
the accumulation of increased amounts of fat in the liver produced detrimental effects 
on health and well-being. Non-alcoholic fatty liver disease (NAFLD) is a metabolic 
disorder which may include simple steatosis characterised by the accumulation of fat 
in the liver which does not originate from an inherent usage of alcohol. NAFLD. Non-
alcoholic steatohepatitis also entails fat accumulation which occurs concomitantly 
with severe inflammation of the liver (Li et al., 2013). 
 
 It is widely believed that NAFLD may be linked to obesity and a sedentary lifestyle. 
As a result, it is sometimes tagged as a disease which is more common among the 
affluent. Statistically NAFLD has been found to be prevalent in the general population 
in North America (34%) and other developed countries such as China (15%) (Dong et 
al., 2012). According to the British Society of Gastroenterology (BSG), 33 % of the 
UK population have NAFLD with 2-5 % progressing to non-alcoholic steatohepatitis 
(NASH) (BSG, 2017).  
 
Various clinical cases attest to NAFLD progressing to fibrosis, cirrhosis and 
hepatocellular carcinoma (Kristin et al., 2009). NAFLD is sometimes described as a 
metabolic syndrome, and also denoted as the most common form liver disease with a 
high prevalence in the general population of Western countries (Bedogni et al., 2005). 
Other diseases for which NAFLD has been reported to be an independent risk factor 
include: hypertension, hypertriglyceridemia and mixed hyperlipidaemia (Targher et 
al., 2010). Furthermore, the pathogenesis of steatosis and cellular injury in NAFLD 
results in insulin resistance hepatic fat accumulation and oxidative stress (Soon Jr et 
al., 2010). Due to the lack of an outright therapy for NAFLD, treatment has been 
mainly focussed on managing the conditions associated with the disease such as 
obesity diabetes mellitus and hyperlipidaemia. Reduction in weight helps to improve 
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the insulin sensitivity and prevent the progression to non-alcoholic steatohepatitis 


















Fig 1.1 An illustration of causative factors of NAFLD and its complications.  Schematic 
depicting the first and second hits in NAFLD with their intermittent events eventually leading 
to liver fibrosis. The first hit comprises of a high fat diet associated with decreased fatty acid 
oxidation, decreased mitochondrial respiration as well as ATP production with an increased 
fatty acid synthesis. The second hit comprises increased inflammation markers notably TNF-
α coupled with increased oxidative stress leading to NASH. High glucose coupled 
hyperinsulinemia leads to fibrosis via the activation of connective tissue growth factor 
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Fatty liver disease is the first stage (i.e. first-hit) in the two-hit model used to estimate 
NASH progression. This stage is propelled by factors such as decreased mitochondrial 
respiration, decreased fatty acid oxidation, decreased ATP production coupled with 
increased fatty acid intake and increased fatty acid synthesis. The second hit causes 
hepatic injury causing an increase in inflammation markers such as TNF- α alongside 
increased oxidative stress. These lead to NASH and then eventually liver fibrosis 
caused by the triggering of connective tissue growth factor (CTGF) by high glucose 
coupled with hyperinsulinemia as shown in Fig 1.1 (Day and James, 1998). The 
proceeding section evaluates the pathogenesis of NAFLD proposed NAFLD therapies 




1.2 Pathogenesis and Therapeutics of non-alcoholic fatty liver disease 
The continuous consumption of a high fat and or carbohydrate diet coupled with a 
sedentary lifestyle promotes the steatosis stage of NAFLD (Raszeja-Wyszomirska et 
al., 2008). As a consequence of this, there is insulin resistance, due to increased levels 
of glucose, free fatty acids (FFAs) and insulin. Increased levels of free fatty acids 
cause a decrease in PPAR-α activity in the liver, resulting in significant reduction in 
β-oxidation. High carbohydrate intake increases expression of PPAR-γ, carbohydrate 
response element-binding protein-1 and sterol regulatory element-binding protein-1 
with a resultant increase in fatty acid synthesis in the liver (Anderson and Borlak, 
2008, Raszeja-Wyszomirska et al., 2008).  
A high fat diet causes Kupffer cells to release pro-inflammatory cytokines TNF-α 
leading to apoptosis and necrosis (Gyamfi and Patel, 2009) as shown in Fig 1.1. 
Silymarin is an active extract from the milk thistle plant (Silybum marianum) which 
has been mostly used in the therapeutic management of liver diseases (Comelli et al., 
2016). Silymarin was also found to protect hepG2 cells against palmitate-induced 
necrosis. Pre-treatment of HepG2 cells with silymarin prevented palmitate-induced 
inhibition of Akt kinase and eventual cell death. Furthermore, other studies suggested 
that silymarin could be an effective phytochemical against saturated fatty acid induced 
cell death in hepatocytes and useful in managing NASH (Song et al., 2007). Hence 
silymarin was used as standard to which the Gentiana plants and phytochemicals were 
compared while investigating their hepatoprotective effects in this research. Fig 1.2 
also shows the assayed possible points of intervention by Gentiana plants after the 
ingestion of a high fat diet. FFAs from high fat diet intake also increased lipid 
peroxidation, tissue inflammation and reactive oxygen species (ROS) such as: 
peroxides, superoxides and hydroxyl radicals leading to elevation of transaminases. 
The ability of gentian to stabilise the levels of transaminase enzymes; the levels of 
which are key determinants of liver diseases was a key feature in studies conducted 
by (Handoussa et al., 2009).  This action is mirrored by ethanol-induced LPS 
activation which also compels Kupffer cells to release pro-inflammatory cytokines 
TNF-α, consequently resulting in apoptosis as seen in the case of a high fat diet. On 
the other hand, decreased PPAR-α level leads to steatosis and a resultant increase in 
serum cholesterol, LDL - C and TG. These avenues serve as points of intervention by 
ostole an O-methylated coumarin which can be isolated from Angelica pubescens 
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which exerts hepatoprotective effects by decreasing TNF-α levels, increasing mRNA 
expression of PPAR-α and decreasing the expression of diacylglycerol 
acetyltransferase, 3-hydroxy-3-methylglutaryl-CoA reductase and cholesterol 7 alpha-
hydroxylase (Sun et al., 2009). Tectoridin which is an isoflavone isolated from 
Pueraria thunbergiana acts by modulating the peroxisome-proliferator activated 





        
 




There are studies which suggest that the administration of ghrelin hormonal therapy  
may have a preventive or therapeutic effect on rat NAFLD models. It was reported 
that ghrelin hormonal therapy caused a significant improvement in NAFLD-induced 
liver injury, oxidative stress, inflammation, and apoptosis by restoring the 
LKB1/AMPK and PI3 K/Akt pathways (Yan et al., 2013). There is no well-established 
therapy for NAFLD, however various therapies used in managing the disease are 
targeted at the risk factors involved in the pathogenesis aimed at reducing or fully 
eliminating any chance of reaching end-stage liver disease. Well-known therapeutic 
measures are centred on lifestyle changes, reducing sedentarism through increased 
physical activity; all with an aim of promoting insulin sensitivity, as well as  using 
medications such as metformin and glibenclamide in the therapeutic process (Raszeja-
Wyszomirska et al., 2008). Other researchers believe that a combination of N-acetyl-
D,L-homocysteine-thiolactone, L-cysteine, and D-fructose can confer a certain degree 
of hepatoprotective effect (Stosiek et al., 2013).  
Fig 1.2 Metabolic pathways of a high fat diet leading to NAFLD. This diagram depicts the metabolic pathways 
of a high fat diet and the sections of this thesis investigating possible points of intervention by Gentiana spp 
and phytochemicals in the fat metabolism pathway. Therapeutic intervention can be produced by silymarin (a 
mixture of flavonolignans extracted from milk thistle (Silybum marianum), osthole: an O-methylated coumarin 
which can be isolated from Angelica pubescens and tectoridin: an isoflavone which can be isolated from 
Pueraria thunbergiana. (Gyamfi, et al, 2009)(Song et al., 2007).  
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1.3 Gentiana Plants, Silymarin and Phytochemicals Used in Treating 
NAFLD 
The roots of Gentiana lutea were used in 180 BC as a tonic and Gentian Macrophylla 
used as the principal plant species in a Chinese folkloric proprietary blend called 
Longdan Xiegan Tang, mainly prepared as a decoction which comprises of other 
plants such as Scutellariae radix, Gardeniae fructus, Alismatis rhizoma, Angelicae 
sinensis, Rehmanniae radix, Glycyrrhizae radix and Plantaginis semen (Wang, 2007). 
The Chinese Materia Medica reports that Gentian causes a reduction in jaundice while 
promoting gall-bladder function (Bensky et al., 2004). Gentian may be prepared as a 
tincture, alkaline mixture or acid Gentian mixture (BP, 2012). There have been 
reported pharmacological properties of Gentiana genus plants attributed to the 
presence of bitter glycosides. Notable phytochemicals found in plants belonging to the 
Gentianaceae family include: getianine, gentisin, amarogentin, gentiopicroside, 
sweroside, swertiamarin, amaroswerin, bellidifolin, swerchirin, norswertianolin and 
gentianadine (Singh, 2008). Gentiana manshurica reduced the serum levels of 
aspartate transaminase (AST) alanine transaminase (ALT) in rats with acute ethanol-
induced hepatitis. It protects hepatocytes from ethanol-induced acute liver steatosis by 
potentially blocking CYP2E1-mediated free radical production and SREBP-1-
regulated fatty acid synthesis (Lian et al., 2010).  
 
There is an increasing interest in discovering and investigating drugs which exhibit 
hepatoprotective actions due to a surge in liver diseases. Statistics showing the spread 
of non-alcoholic fatty liver disease (NAFLD) quotes a figure of between 20–42% in 
the Western hemisphere and up to 24% in China (Amarapurkar et al., 2007).   
There is an evident characterisation of liver damage portrayed through increased lipid 
peroxidation and depletion of glutathione levels (Rao and Raju, 2010). Although the 
precise mechanisms responsible for NAFLD are poorly understood, reports have 
shown perturbed mitochondrial function is central to the pathology, as fatty acids 
cause reduced mitochondrial respiration, increased free radical production and cell 
death (Gyamfi and Patel, 2009, Patel et al., 2007). 
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Silymarin is a mixture of flavonolignans extracted from milk thistle consisting of: 
silybin A, silybin B, isosilybin A, isosilybin B, silydianin and silychristin (Lee and 
Liu, 2003). It has also been found to significantly reduce the levels of elevated hepatic 
enzymes: aspartate transaminase (AST) and alanine transaminase (ALT) (Solhi et al., 
2014). Silybin A and B reduces the effect of NAFLD by scavenging reactive oxygen 
species and inhibiting the membrane absorption of phalloidine (an F-actin) and α-
amanitine (a toxin). This is achieved by preventing phalloidin from binding to the cell 
surface whilst diminishing the membrane transporting system. The silybins have a cell 
membrane as well as cell nuclei effect whereby they increase the ribosomal synthesis 
of proteins by simulating the polymerases and RNA transcription. The reinvigoration 
of protein synthesis is a key step in repairing liver tissue damaged as a result of 
inflammation stemming from NAFLD (Hajaghamohammadi et al., 2008). Supporting 
this point, invitro studies by (Fuchs et al., 1997) suggest that silybin, which is the main 
component of the flavonoid silymarin scavenged free radicals and stimulated 
hepatocyte RNA synthesis while suppressing the growth of hepatic stellate cells and 
the accumulation of collagen. After inducing fibrosis in rats, silybin was found to 
decrease the deposition of collagen and lipid peroxidation (Trappoliere et al., 2005). 
The antioxidant properties of silymarin have been demonstrated in both in vitro and in 
vivo studies (Wellington and Jarvis, 2001) 
Plants such as: Andrographis herba, Glycyrrhizae radix et rhizoma, Ginseng radix, 
Lycii fructus, Coptidis rhizoma have all been categorized as hepatoprotective plants 
with anti-inflammatory and free-radical scavenging abilities. Berberine and 
resveratrol have been studied as bioactive compounds used in the treatment of 
NAFLD. Resveratrol’s mechanism of action entails cell signalling, anti-apoptosis, 
gene expression and prevention of oxidative injury (Kovacic and Somanathan, 2010). 
As shown in Table 1.3 resveratrol which has a polyphenolic structure can be obtained 
from red grapes and other plants including Rhizoma Polygoni Cuspidati and Veratrum 
Nigrum whereas berberine which is an alkaloid, can be found in Coptis chinensis.  
Apart from initiating hypoglycaemic effects, berberine is also believed to activate 
adenosine monophosphate-activated protein kinase (AMPK) which is a serine/protein 
kinase actively involved in the regulation of cellular metabolism. Resveratrol exhibits 
an anti-lipogenic action by up-regulating the FOXO-1 signalling pathway leading to a 
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reduced expression of SREBP-1, acetyl-coA carboxylase (ACC) and fatty acid 
synthase (FAS) with a combined effect of reduced lipogenesis and eventually a 
marked reduction in hepatic storage. Hepatic inflammation is also reduced through the 
decreased expression of TNF-α (Wang et al., 2009b). This is further depicted by the 
schematic in Fig 1.2. Table 1.3 presents a summary of hepatoprotective 






























Table 1.3 Summary of hepatoprotective phytochemicals and their bioactivities 
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This study focused mainly on the secoiridoid glycoside phytochemicals found in 
Gentiana plants i.e.: gentiopicroside, swertiamarin and sweroside. This is because, 
these phytochemicals have been shown to possess hepatoprotective effects but have 
not been extensively researched (Chen et al., 1993).  At a dose of 25 -50 mg/kg mice 
body weight, gentiopicroside and sweroside showed hepatoprotective effects against 
d-galactosamine/lipopolysaccharide-induced liver injury (Lian et al., 2010). 
Furthermore, the administration of swertiamarin at a dose of 100-200 mg/kg mice 
body weight prior to exposure to d-galactosamine exerted hepatoprotective effects by 
prevented the alteration of several hepatic parameters and reduced lipid peroxidation 
as well as oxidative stress significantly (Jaishree and Badami, 2010) 
  
           
 
                                     
 
Gentiana lutea was found to possess hepatoprotective, anti-inflammatory and 
hypoglycaemic effects (Balijagić et al., 2012). GPS (Fig. 1.3), present in most Gentian 
spp has shown hepatoprotective activity in mice intoxicated with carbon tetrachloride 
CCl4 (Wang et al, 2010). Substantial amounts of gentiopicroside can be found in 
Gentiana lutea, Gentiana macrophylla, Gentiana rigescens and Gentiana scabra 
(Rahman, 2006). Despite the widespread use of Gentian spp there have been few 
studies on how the root extracts of the herb can be used as hepatoprotective agents. 
Hence this study investigates extracts of the four-above-named species of Gentiana 
and their phytochemicals to determine whether or not they possess any 
hepatoprotective characteristics and also compare them to determine the most viable 
species among them in this regard. Table 1.4 reviews some investigations already 
carried out on Gentiana plants, their aims and objectives, methodology employed, 
outcomes and comments on areas not covered in that spectrum which this research 
aims to help build up on. 
Fig. 1.3 Gentiopicroside, GPS 
Table 1.4 Summary of Research Conducted on Gentiana Plants 
Title/Ref.  Aims and 
Objectives 
Methodology Results Comments 
Preliminary results on 
study of the 
hepatoprotective and 
antimicrobial effects of 
Gentiana asclepiadea 
ethanolic extract 
(Suciu et al., 2012) 
To demonstrate the 
hepatoprotective 
and antimicrobial 
effects of gentian. 
The active principles 
were extracted in 80% 
ethanol for 24hrs and 
analyses using a GC-
MS. The extracts were 
administered to mice; 
and a liver 
transaminase 
analysis, histology and 
ultrastructural analyses 
of the liver conducted 
along with GC-MS 
analysis of the 
extracts, and 
microbiology tests 
against a number of 
pathological strains 
 
The ethanolic extract of Gentiana 
asclepiadea had a hepatoprotective effect, 
as shown by the enzyme analysis where it 
reduced the ALT and AST levels in 
comparison to 
the control group, and the histology and 
ultrastructure analyses, both of which 
showed a decrease in cellular degradation 
as compared to the positive and negative 
control groups. 
 
 CTRL INTOX TREAT 
AST 
(U/L) 
278 1012 463 
ALT 
(U/L) 
137 219 70 
 
Histologically, the gentian treated group 
showed less amounts of lipids compared to 
the intoxicated group. 
This study was useful in 
depicting gentian as 
having hepatoprotective 
properties. However, the 
study did not identify 
and quantitate 
phytochemicals in the 
bioactive fractions. It 
also focused mainly on 
the transaminases and 




potential), reduction of 
oxidative stress (free 
radical levels, 
antioxidant status, 
cytochrome c release). 
Finally, the study did 
not provide a clear 
understanding of the 
mechanism of action of 
phytochemicals in 
Gentiana asclepiadea. 
Hence the need for a 
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study to investigate 
these phytochemicals. 
Chemical profile, 
radical scavenging and 
cytotoxic activity of 
yellow gentian leaves 
(Gentiana lutea) 
grown in northern 
regions of Montenegro 
(Balijagić et al., 2012) 




activity of yellow 
gentian leaves 
LC-ESI-MS and HPLC 
were used for the 
identification of the 
constituents from 
Gentiana lutea leaves 
collected at different 
localities, as well as for 
quantification of the 
main compounds. 









pyrones and altitude 
was observed with 
statistically significant 
correlation (r = 0.94). 
The extracts were also 
evaluated for their 
content of total 
phenolics, and 
The leaf extract exhibited moderate 
cytotoxic effects toward HeLa cells with an 
IC50 value of 41.1 microg/mL, while 
gentiopicrin, mangiferin and isogentisin 
exerted strong activity against HeLa cells, 
with IC50 values ranging from 5.7 to 8.8 
microg/mL. The results confirm the 
traditional usage of Gentiana lutea leaves 
and suggest their possible utilisation as 
hepatoprotective, hypoglycemic and anti-
inflammatory agents. 
This investigation 
placed more focus on 
the chemical profile of 
Gentiana lutea and its 
potential cytotoxic 
properties but was not 
fully focused on 




property prompting the 
need for further study to 
determine this. The 
study also did not 
examine the mechanism 






Spicatic acid: A 4-
carboxygentisic acid 
from Gentiana spicata 
extract with potential 
hepatoprotective 
activity (Handoussa et 
al., 2009) 
To investigate the 
hepatoprotective 
activity of the 
aqueous alcoholic 




treated rats was 
investigated. 
A concentration of 1 
mL/kg CCl4 used and 
results derived by 
comparing the effects 
of pre-treatment with 
plant extracts.  
The levels of alanine aminotransferase 
(ALT) and aspartate aminotransferase 
(AST) increased upon treatment with CCl4. 
However, pre-treatment with gentian and its 
individual components significantly 
prevented the increase in these enzymes, 
which are the major indicators of liver 
injury. 
This study also focused 
more on the 
transaminases and not 
mitochondrial function 
and membrane potential. 
Furthermore, 
quantitation and 
collation of bioactive 
phytochemicals were 
not carried out. 
Hepatoprotective 
effects of Gentiana 
scabra on the acute 
liver injuries in mice 
(Jiang and Xue, 2005)  
To study the 
hepatoprotective 
effect of the aerial 
parts and the roots 
of Gentiana scabra 
on acute liver injury 
models. 
Acute liver injury 
models were induced 
by CCl4, TAA 
(thioacetimidic acid) 
and D-GlanN in mice, 
and the levels of serum 
enzyme ALT, AST and 
ALP on acute liver 
injury mice with 
extracts of the aerial 
parts and the roots of 
Gentiana scabra 
determined. 
Different dosages of the aerial part extract 
could significantly reduce the levels of 
serum enzyme ALT, AST and ALP (P < 
0.05) on CCl4 and TAA model mice, but 
the serum enzymes reduction of D-GlanN 
model mice was not significant. 
This study also focussed 
mainly on the 
transaminases and on a 
single bioactive 
compound: 
succedaneum and did 
not seek to identify and 
quantify other bioactive 
phytochemicals. It also 
failed to elucidate a 





effects of bitter 
principles isolated 
from gentian root and 
swertia herb on 
experimentally-
induced gastric lesions 






extract of gentian 
root using different 
gastric lesion 
models 
Gentian extracts were 
orally and duodenally 
administered in rats 
with acute gastric 
ulcer induced by 





mucosal injury induced 
by ethanol 






from gentian root or 
swertia herb, were 
studied for 






rats, administration of gentian in the 
duodenum suppressed 
gastric juice secretion and total acid output 
in a dose-dependent 
manner. Oral or duodenum administration 
of 
gentian showed significant protection 
against acute gastric 
ulcer induced by aspirin plus pylorus 
ligation, water immersion 
restraint stress-induced ulcers, and gastric 
mucosal injury induced by ethanol. 500 
mg/kg completely 
suppressed gastric juice secretion, but had 
no 
effect on ethanol-induced gastric mucosa 
damage at 
1,000 mg/kg. Gentiopicroside obtained 
from n-BuOH soluble fraction of gentian 
root also had no effect. In contrast, 125 
mg/kg ethyl acetate soluble fraction of 
gentian root had no effect on gastric juice 
secretion, but significantly protected 
against ethanol induced 
mucosal damage 
This study focused more 
on the gastroprotective 
phase of gentian’s broad 
range of effects but 
raised the possibility of 
gentian being a 
hepatoprotective. 
Building up on this 
information, 
gentiopicroside was 
examined for effects 
from a hepatoprotective 
point of view in this 
research rather than a 
gastroprotective point of 





This study will examine the hypothesis that the methanolic extracts and selected 
phytochemicals of the four Gentiana species: lutea, macrophylla, rigescens and scabra 
exhibit hepatoprotective effects in non-alcoholic fatty liver disease (NAFLD).  
1.5 Aim  
To investigate the means by which hepatocyte protection is conferred by Gentiana 
plants used in herbal medicine for the treatment of non-alcoholic fatty liver diseases 
(NAFLD). 
1.6 Objectives  
1. To assess Gentiana spp. extracts in order to: 
i. Identify some known phytochemicals in the extracts by HPLC and 
HPTLC.  
ii. Quantify selected phytochemicals in the Gentiana spp extracts by 
HPLC prior to screening on hepatocytes to determine their bioactivity. 
2. To screen in vitro, the resistance of hepG2 and THLE-2 cells to fatty acid 
(arachidonic acid) induced cytotoxicity in the presence of Gentiana spp. as 
follows:  
i. Pre-treatment of hepG2 cells with Gentiana spp followed by fatty 
acids treatment. 
ii. Co-administration of Gentiana spp and fatty acids to hepG2 cells. 
iii. Post-treatment of hepG2 cells with Gentiana spp after they have been 
exposed to fatty acids 
3. To investigate the effects of bioactive Gentiana spp. extracts and 
phytochemicals on mitochondrial function, apoptosis and reduction of 
oxidative stress on HepG2 cells in the presence of fatty acids in order to: 
i. Understand and evaluate the mode of hepatocyte protection conferred 
by bioactive extracts and phytochemicals in acting at cellular and 
molecular levels in the treatment of NAFLD. 
ii. Propose synergistic combinations of Gentiana spp. phytochemicals in 

















Chapter 2. Qualitative and Quantitative Analysis of 





2.1 Introduction  
 Gentiana lutea, Gentiana macrophylla, Gentiana scabra and Gentiana rigescens 
shown in Fig 2.1 are four species plants found in the Gentianaceae family of flowering 
plants which is composed of approximately 900-1200 species (Daniel and Sabnis, 
1978).  
Morphologically, Gentiana lutea possesses yellow flowers with spaces of 5 to 10 cm 
in-between, arising from four to ten pairs of pseudo-umbels (Kery et al., 2000). 
Gentiana macrophylla has ovato-elliptic and narrowly elliptic late basal leaves and 
dark-blue corolla (Zhao et al., 2010). In terms of Gentiana scabra, the flowers and 
leaves are sessile and opposite. The calyx is conical, membranous and has a measure 
of 1 cm. The leaves of Gentiana rigescens are simple, sessile and opposite. It has 
flowers which are also sessile with a 1 cm long calyx as well as a violet corolla which 
is bell-shaped and 2.5 cm long. Furthermore, it has a cuneate blade with nerves 




Fig 2.1. Flowering parts of Gentiana spp. Flowering parts of: (A) Gentiana lutea, (B) 











There are variable methods used to extract dried and powdered roots of Gentiana 
species; most notable among them being methanolic extraction via sonication and 
methanolic extraction via refluxing in the presence of a heat source. According to the 
Chinese pharmacopoeia, 5g of Gentiana species root extract can be extracted with 20 
mL of methanol under reflux for 30 min. The extract obtained is then evaporated under 
reduced pressure to dryness (Zhonghua Renmin, 1997). In another instance, 1 g of 
Gentiana species root powder was extracted using 10 mL of ethanol, refluxed for 30 
mins and evaporated to dryness (Wagner et al., 2016). 
It has been reported that the powdered root of Gentiana macrophylla (10 mg) was 
extracted with methanol (10 mL) via sonication for 45 min at room temperature, 
yielding a drug/extract ratio of 35.2% (w/w) (Mustafa et al., 2015).  Sonication 
extraction method was also used by Hayata et al., (2011) to extract Gentiana cruciata 
(100 mg) in 2 mL of methanol at room temperature. After HPLC, the dominant 
phytochemical elucidated was gentiopicroside 2.86% (w/w). Furthermore, Gentiana 
macrophylla, Gentiana. straminea, Gentiana crassicaulis, Gentiana dahurica, 
Gentiana officinalis and Gentiana siphonantha were extracted via sonication with 
methanol 20 mL at room temperature for 40 min (Cao and Wang, 2010).  
As far as refluxing is concerned, methanolic extraction via refluxing was used in the 
extraction of dried root powder of Gentiana lutea (15 g) by refluxing the powder for 
40 min in 180 mL of methanol. Quantitative HPLC assay of the extract yielded 
gentiopicroside, loganic acid and swertiamarin (46.3, 10.8 and 4.1 g/kg). Using this 
method, 1 g of dried Gentiana lutea root was refluxed with methanol 10 mL, for 10 
min followed by filtration (Camelia et al., 2008). Gentiana rodentha was successfully 
extracted by refluxing thrice with methanol leading to the identification, quantitation 
and isolation of rodenthoside via NMR and HPLC (Ma et al., 1994). Table 2.1 presents 
a compilation of Gentiana species extraction methods and findings. 
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Table 1.1 Compilation of Gentiana spp extraction methods and findings 




Gentiana lutea (1 g) Sonication GPS (3.53 % g/g) 
SWE (0.15% g/g) 




Sonication GPS (9.7±2.0 %) 
 








(Cao and Wang, 
2010) 
Gentiana scabra (0.1 g) Sonication GPS (2.27 mg/g) 
SWE 0.0162 mg/g) 










(Pan et al., 2015) 
Gentiana lutea (15 g) Refluxing GPS (28.2-62.6 
g/kg) 
SWT (4.8 – 15.5 
g/kg) 




Refluxing GPS (N/A) (Yu et al., 2004) 
Gentiana rigescens 
 (2 g) 
Refluxing Extract: material 
ratio (1:4-1:12 
g/mL) 
(Chu et al., 2015) 
Key: GPS- Gentiopicroside; SWE- Sweroside; SWT- Swertiamarin 
Apart from the above-mentioned researchers who quantitated phytochemicals in 
Gentiana spp. using HPLC, other researchers have also used HPLC, although with 
adapted variations to suit their intended outcomes.  After extracting 0.5 g powdered 
roots of Gentiana manshurica, Gentiana scabra, Gentiana triflora and Gentiana 
rigescens in methanol (10 mL) under ultrasound both gradient and isocratic HPLC 
conditions were used to quantify phytochemicals present in the plant species. The 
mobile phase used consisted of H2O and CH3CN as follows: isocratic - H2O (80%): 
acetonitrile CH3CN (20%); whereas for gradient, 0-22.5min - H2O (90%): CH3CN 
(10%) and then 22.5 – 25min H2O (80%): CH3CN (20%). UV spectra were measured 
with a diode-array detector from 200 to 400 nm (Jiang et al., 2005). A gradient 
condition entailing aqueous phosphoric acid (0.4 %) was used linearly with methanol 
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(10-40 %) between 0 – 40 min with 5 µL of samples injected at a flow rate of 1 mL/min 
and detection wavelength 242 nm. The study resulted in the quantitation of loganic 
acid, swertiamarin, sweroside and gentiopicroside (6.4, 7.8, 65.4 and 0.1 mg/g) (Cao 
and Wang, 2010). Table 2.2 presents Gentiana species HPLC methods and conditions 
Table 2.2 Gentiana spp HPLC methods and conditions 




Column Mobile Phase Phytoche
micals 
Ref. 






















GL Gradient 254&280 C18 5 
µm 














m et al., 
2007) 





forminc acid in 


















Besides the use of HPLC, other researchers validated HPLC outcomes via high 
performance thin layer chromatography (HPTLC) which uses very high-resolution 
silica plates in a fully automated system which minimises the influence of human error 
experienced in conventional TLC. HPTLC has been used for the quantification of 
gentiopicroside in the root extracts of Gentiana lutea as well as for qualitative 
purposes (Bodart et al., 1996). Swertiamarin and amarogentin have been quantified 
from Swertia species by HPTLC using ethanol, methanol and water. The recovery of 
amarogentin and swertiamarin was 94.5 % and 96.5 % respectively (Bhandari et al., 
2006). Gentiana rigescens extracts were analysed with HPTLC using a solvent 
mixture: toluene and ethyl acetate (15:1). The data obtained were analysed using three 
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multivariate analysis namely principal component analysis, partial least squares 
discrimination analysis (PLS-DA) and orthogonal PLS-DA. HPTLC model score plot 
showed excellent spatial distribution in all three multivariate analysis stated above. 
This outcome, coupled with the reproducibility and predictivity of results confirmed 
HPTLC as a robust method for qualitative and quantitative analysis of Gentiana plants 
(Ogegbo et al., 2012). 
Profiling Gentiana plants extracted through sonication or refluxing is a key step in 
obtaining a clear overview of phytochemicals present in the plants. The application of 
HPLC and HPTLC qualitative and quantitative methods provides further verification 
of the authenticity of the plants while serving as a reference point for understanding 
and tracing bioactive fractions of the plant extracts. 
  
2.2 Aim 
The investigations carried out in this chapter aimed at employing sonication and 
refluxing extraction techniques to extract Gentiana lutea (GL), Gentiana macrophylla 
(GM), Gentiana scabra (GS), and Gentiana rigescens (GR), after which high 
performance liquid chromatography (HPLC) and high performance thin layer 
chromatography (HPTLC) were used to qualitatively and quantitatively assess 
inherent phytochemicals. Gaining a clear understanding and estimations of three 
phytochemicals (gentiopicroside, sweroside and swertiamarin) in the Gentiana 
species: lutea, macrophylla, scabra and rigescens helped to portray an overview of 
the chemical nature of the plant extracts and outlined the basis for invitro tests carried 
out in chapter 3 on the hepatocytes. 
2.3 Materials and Methods 
2.3.1 Extraction of Gentiana spp. via Refluxing Extraction Method  
Gentiana spp. extracted were Gentiana lutea (GL), Gentiana macrophylla (GM), 
Gentiana scabra (GS), and Gentiana rigescens (GR). Powdered roots were procured 
from (Beijing Tong Ren Tang, UK) and verified by Botanist Prof. Peter Li Hong Wu 
(Shanghai University of Traditional Chinese Medicine, China). Gentiana spp. root 
powder (5 g) was extracted in methanol/distilled water (75:25) by refluxing for 30 
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min, and the extracts were filtered via Buchner filtration and then rotary evaporated to 
dryness. After rotary evaporation, the extract was freeze-dried for 72 h.  
2.3.2 Gentiana spp. Extraction via Sonication  
The four Gentiana species mentioned in section 2.3.1, 0.2 g each was weighed and 
extracted with methanol (5 mL) and ultrasonicated for 30 min at room temperature. 
The extracts were centrifuged at 5000 rpm for 10 min and supernatants were filtered 
with a 0.22 μm pore membrane (Merck, Ireland) into vials for use in HPLC and 
HPTLC.    
2.3.3 Preparation of Standard Phytochemicals: Gentiopicroside, Sweroside and 
Swertiamarin 
For HPTLC analysis, gentiopicroside (Abcam, UK) 200 μg/mL, sweroside (Sigma-
Aldrich, UK), 200 μg/mL and swertiamarin (Sigma-Aldrich, UK) 200 μg/mL were 
prepared in methanol. An initial stock solution was made for each phytochemical and 
then diluted to the desired concentration. Standards of the four phytochemicals for 
HPLC were prepared as follows: 0.5, 1, 5, 10, 15, 20 and 50 μg/mL in methanol. 
2.3.4 HTPLC Analysis of Gentiana spp. 
HPTLC was performed using the CAMAG ADC2 (CAMAG, Switzerland). Stationery 
phase used was 10x10 cm HPTLC plates silica gel 60 F 254 (Merck, UK), whereas a 
mobile phase comprising of ethyl acetate: methanol: water (10:2:1) was utilised at a 
solvent front position of 70 mm. For every specie of Gentian, methanolic extract (3 
μL) was injected per HPTLC run, whereas gentiopicroside (3 μL) of 200 μg/mL 
standard solution was applied per run.  After initial visualization, plates were 
immersed into H2SO4 (10%) for two seconds, dried on TLC plate heater at 105°C for 




2.3.5 HPLC Analysis of Gentiana spp. 
2.3.5.1 Isocratic HPLC Method for Qualitative Assessment of Gentiana spp. 
Extracted by sonication. 
As part of qualitative experiments an isocratic RP-HPLC of the Gentian spp. extracted 
via sonication and gentiopicroside (standard) was performed using DIONEX AS50 
(DIONEX, USA). Stationary phase used was Kinetex C18 150x4.6 mm (Phenomex, 
USA). A mobile phase consisting of methanol/water (18:82) was utilised in an 
isocratic manner at a flow rate of 1 mL/min and injection volume of 10 μL for each 
specie of Gentiana. Each specie was run for 45 min and detected at 233, 254 and 270 
nm. Retention times and peak areas were noted and compared to that of the standard 
(gentiopicroside) prepared in section 2.33.  
 
2.3.5.2 Gradient HPLC Method for Qualitative and Quantitative Assessment of 
Gentiana spp. 
 
Qualitative and quantitative gradient HPLC was performed on Gentiana spp. and 
standards: gentiopicroside, sweroside and swertiamarin with Ultimate 3000 (Thermo 
Fisher Scientific, UK) using a stationary phase Kinetex C18 150x4.6 mm (Phenomex, 
USA). A mobile phase comprising of methanol/water with methanol (5-70 %) between 
0 – 25 min gradient was utilised and 10 µL of samples injected at a flow rate of 1 
mL/min. Peaks were detected at wavelengths 233, 254 and 270 nm after which peak 
areas were collated and used in quantifying phytochemicals presents via calibration 
curves. This assay was carried out for the four Gentiana species extracted by both 
refluxing and sonication after which quantities of phytochemicals were compared. The 
R square values and linear equations of the calibration curves were also noted and 
presented in Table 2.5. 
 
2.3.6 Method Validation and Statistics 
The reference standard solutions of gentiopicroside, sweroside and swertiamarin were 
prepared for a seven-point calibration curve by accurately weighing, dissolving in 
methanol and diluting as follows: 0.5, 1, 5, 10, 15, 20 and 50 μg/mL. Triplicate 
injections were made at each of the seven different concentrations. The linearity of 
each standard curve was made by plotting the peak area against concentration. The 
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resultant calibration curves were used in calculating the quantities of phytochemicals 
present in the four Gentiana species tested. The limit of detection (LOD) and 
quantitation (LOQ) under the chromatographic conditions were determined at signal-
to-noise ratios (S/N) of 3 and 10, respectively. R2 values of calibration curves ranged 
from 0.9958 – 0.9983. Relative standard deviation (RSD) of retention times for 
isocratic qualitative assessment given. All results given as ± standard deviation and 
are average values from three to five runs per sample in each experiment; which were 





2.4.1 HPTLC Profile of Gentiana: lutea, macrophylla, scabra and rigescens 
A preliminary study to determine the phytochemical components of Gentian spp. was 
conducted via HPTLC analysis which showed the presence of gentiopicroside in all 
four species of Gentian (Fig 2.2.). For gentiopicroside, an Rf value of 0.51 was 
recorded. The chromatogram for Gentiana lutea appeared to have a vast array of bands 
which were also higher in intensity when compared to the three remaining Gentiana 
species. This was followed by Gentiana scabra, Gentiana macrophylla and Gentiana 




Fig 2.2 HPTLC of Sonicated Gentiana Spp. Preliminary Priming HPTLC run of 
200 µg/mL sonicated Gentiana lutea (2), Gentiana macrophylla (3), Gentiana scabra 
(4) and Gentiana rigescens (5) alongside standard (gentiopicroside) (1) with a band 
depicting the presence of gentiopicroside with RF value 0.51 in all four Gentiana spp. 




In the follow-up HPTLC assays, bands representing other phytochemicals (sweroside 
and swertiamarin) which were also identified alongside gentiopicroside as shown in 





Fig 2.3 HPTLC of sonicated Gentiana spp. compared with three reference 
standards. HPTLC run of refluxed 200 µg/mL Gentiana lutea (3), Gentiana 
macrophylla (4), Gentiana scabra (5) and Gentiana rigescens (6) alongside 
standards: gentiopicroside (1), sweroside (2) and swertiamarin (7) with bands 
depicting the presence of gentiopicroside (RF= 0.51), sweroside (RF=0.55) and 




1 2 3 4 5 6 7 
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Fig 2.4 HPTLC of Refluxed Gentiana spp. compared with three reference 
standards.  HPTLC run of refluxed 200 µg/mL Gentiana lutea (3), Gentiana 
macrophylla (4), Gentiana scabra (5) and Gentiana rigescens (6) alongside 
standards: gentiopicroside, sweroside and swertiamarin with bands depicting the 
presence of gentiopicroside (RF= 0.51), sweroside (RF=0.55) and swertiamarin 
(RF=0.46) in all four Gentiana spp. under 366 nm developed remissions 
 
 
It was generally observed that bands generated for the refluxed Gentiana species were 
slightly more intense compared to bands from the sonicated Gentiana species. 
However there remained similarities between inter-species comparison of bands 
derived from Gentiana species extracted via both refluxing and sonication. Two 
distinctively intense green bands were observed for Gentiana lutea extracted by both 
refluxing and sonication. Table 2.3 presents a summary of Rf values for 

















%RSD of retention time =0.45 
2.4.3 HPLC Profile of Gentiana: lutea, macrophylla, scabra and rigescens 
Further preliminary qualitative testing of Gentiana spp via HPLC (isocratic run) 
produced similar chromatograms for all four Gentian species with peak areas and 
retention as shown in (Fig.2.2). Drawing a comparison between these chromatograms 
and that of the standard (gentiopicroside), there was an indication of the presence of 
gentiopicroside in each of the Gentian species tested. The average retention time for 
gentiopicroside was 14.25 min (RSD 0.45 %) with the highest peak area of 12.8 mAU 
observed for Gentiana lutea (Table 2.5). This was followed by Gentiana scabra, 
Gentiana macrophylla and Gentiana rigescens in order of decreasing peak area. 
 
Table 2.4 Comparison of Gentiopicroside Retention Times and Peak Areas 
Derived by Isocratic HPLC 
SAMPLE NAME RET. TIME (Min) AREA MAU*min 
Gentiopicroside 14.250 0.560 
Gentiana lutea 14.267 12.797 
Gentiana macrophylla 14.300 5.163 
Gentiana scabra 14.267 11.665 

























Fig. 2.5. Qualitative isocratic RP-HPLC assay of Gentian spp. The chromatograms portray 
gentiopicroside bands in all four Gentiana species. RP-HPLC chromatogram: Gentiana lutea (1), 
Gentiana macrophylla, Gentiana scabra and Gentiana rigescens. Each species of Gentian contained 









In order to obtain a full spectrum of phytochemicals present in the four Gentiana 
species, gradient HPLC was run which showed peaks representing gentiopicroside, 
sweroside and swertiamarin in each of the four Gentiana species (Fig 2.6). The average 
retention times were as follows: gentiopicroside (12.4 min), sweroside (12.9 min) and 
swertiamarin (11.7 min). Apart for the three afore-mentioned phytochemicals, other 
peaks also observed in the chromatograms obtained for each of the four Gentiana 
species. Notably in Gentiana lutea, the highest array of different peaks were observed 
which seemed to shed more light on the multiple bands observed in the HPTLC ass of 






Fig 2.6 RP-HPLC-DAD Chromatograms of Gentiana spp extracted by sonication. HPLC chromatograms at 
233 nm showing the phytochemical profile of Gentiana lutea, Gentiana macrophylla, Gentiana scabra and 
Gentiana rigescens extracted by sonication with identified phytochemicals: (1) gentiopicroside (ret time 
12.413), (2) sweroside (ret time 12.94) and (3) swertiamarin (11.717). Lutea species presents the highest 












HPLC analysis of Gentiana species extracted by refluxing produced chromatograms 
in all four Gentiana species which were similar to chromatograms observed for 
Gentiana species extracted by sonication. The presence of gentiopicroside, sweroside 
and swertiamarin was also confirmed in each of the four species as shown in Fig 2.7. 
with retention times similar to those stated for the sonicated extracts. In this instance 
Gentiana lutea presented the most dominant array of peaks followed by Gentiana 
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Fig 2.7 RP-HPLC-DAD Chromatogram Overlay for Gentiana spp extracted by refluxing. 
HPLC Chromatograms overlay showing the phytochemical profile of Gentiana lutea, Gentiana 
macrophylla, Gentiana scabra and Gentiana rigescens extracted by refluxing aligned with 
standards phytochemicals: (1) gentiopicroside (ret time 12.413), (2) sweroside (ret time 12.93) 
and (3) swertiamarin (ret time 11.717) at 233nm.  
 
Gentiana lutea 








Quantitation of gentiopicroside, sweroside and swertiamarin was initiated by 
calibration of the standards at seven concentration points (0.5, 1, 5, 10, 15, 20, and 50 
µg/mL). Details of intra-day gentiopicroside calibration tables can be found in 
Appendix A. As shown in fig 2.8 a mixture of the reference standards produced three 
peaks at 233 nm representing gentiopicroside, sweroside and swertiamarin.  A liner 
equation of y=0.1371x + 0.0592 and R square value of 0.9982 was obtained for 
gentiopicroside as seen in Fig 2.9. There was a linear correspondence of 













Fig 2.8 RP-HPLC-DAD Chromatograms of combined reference standards. HPLC chromatograms at 
233 nm showing standard phytochemicals: (1) gentiopicroside (ret time 12.413), (2) sweroside (ret time 





Fig 2.9 A graph of gentiopicroside peak area against concentration. Calibration 
curve of gentiopicroside at concentrations 0.5, 1, 5, 10, 15, 20 and 50 µg/mL with line 
equation y=0.137x+0.0592 and R2 value of 0.9982 





























For sweroside, calibration was conducted at concentration points (0.5, 1, 5, 10, 15, 20, 
and 50 µg/mL). A rise in sweroside concentration corresponded with an increment in 
peak area represented by line equation y = 0.3043x + 0.0163 and R square value of 
0.9998 as seen in Fig 2.10. Intra-day calibration tables for each of the seven 





Fig 2.10 A graph of sweroside peak area against concentration. Calibration curve 
of sweroside at concentrations 0.5, 1, 5, 10, 15, 20 and 50 µg/mL with line equation 








































Fig 2.11 A graph of swertiamarin peak area against concentration. Calibration 
curve of swertiamarin at concentrations 0.5, 1, 5, 10, 15, 20 and 50 µg/mL with line 
equation y=0.3159x+0.0802 and R2 value of 0.999 
 
 
Calibration of swertiamarin at concentration points (0.5, 1, 5, 10, 15, 20, and 50 
µg/mL) corresponded linearly to rise in peak areas with a line equation y = 0.3159x + 
0.0792 and R square value of 0.999 as shown in Fig 2.10. Detailed calibration tables 
for swertiamarin can be found in Appendix C. 
As shown in Table 2.5 limit of detection (LOD) values of gentiopicroside were 
calculated 0.00153 with 0.00160 for sweroside and 0.00146 for swertiamarin. Limit 
of quantitation (LOQ) values calculated for gentiopicroside, sweroside and 
swertiamarin were (0.0153, 0.0160 and 0.0146) respectively. 
 
Table 2.5 Summary Calibration Table for Gentiopicroside, Sweroside and 
Swertiamarin 
Compound Regression Equation R2 LOD LOQ 
Gentiopicroside y=0.137x+0.0592 0.9982 0.00153 0.0153 
Sweroside y=0.3043x+0.0163 0.9998 0.00160 0.0160 
Swertiamarin y=0.3159x+0.0802 0.9991 0.00146 0.0146 
 
  




























As shown in Table 2.6 inter-day HPLC precision of gentiopicroside found in 200 
µg/mL Gentiana lutea extracted by refluxing produced peak areas comparable to intra-
day figures for the same amount of Gentiana lutea refluxed extracts. Gentiopicroside 
inter-day peak areas ranged from 2.8199-2.8921 mAU*Min whereas an average of 
2.7547 mAU*Min was recorded intra-day.  
Sweroside inter-day peak areas ranged from 0.1251-1.1424 mAU*Min with averaged 
0.1184 mAU*Min intra-day.  
Swertiamarin yielded inter-day peak areas ranging from 0.4083-0.4329 mAU*Min 
which was similar to the averaged intra-day peak area of 0.4437 mAU*Min. RSD 
values of gentiopicroside, sweroside and swertiamarin for both inter-day and intra-day 
precision studies were below 1 % as seen in Table 2.6. 
 Further intra-day precision data for peak areas of gentiopicroside, sweroside and 
swertiamarin obtained from 100, 500 and 1000 µg/mL Gentiana lutea extracted by 





Table 2.6 Intra-day and Inter-Day HPLC Precision of Gentiopicroside, 
Sweroside and Swertiamarin in Refluxed Gentiana lutea Based on Peak Areas 
with RSD 
 
 Inter-day (n=3) Intra-day (n=3) 
















































In the case of 200 µg/mL Gentiana lutea extracted by sonication, inter-day peak areas 
obtained for the three phytochemicals were comparable to the intra-day peak area 
average.  Gentiopicroside yielded 0.8427-0.8548 mAU*Min comparable to an intra-
day average of 0.8359 mAU*Min as seen in Table 2.7.  
The inter-day values obtained for sweroside ranged from 0.0382-0.04217 mAU*Min 
compared to 0.04031 mAU*Min intra-day. Swertiamarin also had inter-day values 
ranging from 0.1147-0.1191 mAU*Min with 0.1149 mAU*Min as intra-day. 
Further intra-day precision data for peak areas of gentiopicroside, sweroside and 
swertiamarin obtained from 100, 500 and 1000 µg/mL Gentiana lutea extracted by 





Table 2.7 Intra-day and Inter-Day HPLC Precision of Gentiopicroside, 
Sweroside and Swertiamarin in Sonicated Gentiana lutea Based on Peak Areas 
with RSD 
 
 Inter-day (n=3) Intra-day 
(n=3) 
(mAU*Min)  








RSD =0.30 % 
0.8583 
SD=0.002 







































As shown in Table 2.8 inter-day HPLC precision of gentiopicroside found in 200 
µg/mL Gentiana macrophylla extracted by refluxing produced peak areas comparable 
to intra-day figures for the same amount of Gentiana macrophylla refluxed extracts. 
Gentiopicroside inter-day peak areas ranged from 0.9917-1.0209 mAU*Min whereas 
an average of 0.9792 mAU*Min was recorded intra-day.  
Sweroside inter-day peak areas ranged from 0.0875-0.0912 mAU*Min with averaged 
0.0872 mAU*Min intra-day.  
Swertiamarin yielded inter-day peak areas ranging from 0.1136-0.1234 mAU*Min 
which was similar to the averaged intra-day peak area of 0.1151 mAU*Min. RSD 
values of gentiopicroside, sweroside and swertiamarin for both inter-day and intra-day 
precision studies as seen in Table 2.8 were low indicating that the data is tightly 
clustered around the mean. 
 Further intra-day precision data for peak areas of gentiopicroside, sweroside and 
swertiamarin obtained from 100, 500 and 1000 µg/mL Gentiana macrophylla 
extracted by refluxing can be seen in Appendices N and P. 
 
Table 2.8 Intra-day and Inter-Day HPLC Precision of Gentiopicroside, 
Sweroside and Swertiamarin in Refluxed Gentiana macrophylla Based on Peak 
Areas with RSD 
 Inter-day (n=3) Intra-day 
(n=3) 
(mAU*Min)  








RSD =0.14 % 
1.0209 
SD=0.002 
























RSD = 2.43 % 
0.1136 
SD=0.001 
RSD= 0.54 % 
0.1140 
SD=0.001 





The results for 200 µg/mL Gentiana macrophylla extracted by sonication presented 
inter-day peak areas for the three phytochemicals comparable to the intra-day peak 
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area average.  Gentiopicroside produced 0.0619-0.0.0671 mAU*Min comparable to 
an intra-day average of 0.06010 mAU*Min as seen in Table 2.9.  
The inter-day values obtained for sweroside ranged from 0.0070-0.00757 mAU*Min 
compared to 0.0083 mAU*Min intra-day. Swertiamarin also had inter-day values 
ranging from 0.0080-0.0084 mAU*Min with 0.0089 mAU*Min as intra-day. Low 
RSD values obtained for inter and intra-day results denoted data clustering around the 
mean. 
Further intra-day precision data for peak areas of gentiopicroside, sweroside and 
swertiamarin obtained from 100, 500 and 1000 µg/mL Gentiana macrophylla 
extracted by sonication can be seen in Appendices O and Q. 
Table 2.9 Intra-day and Inter-Day HPLC Precision of Gentiopicroside, 
Sweroside and Swertiamarin in Sonicated Gentiana macrophylla Based on Peak 
Areas with RSD (in parenthesis) 
 
 
 Inter-day (n=3) Intra-day 
(n=3) 
(mAU*Min)  








RSD =0.43 % 
0.0647 
SD=0.0006 


































RSD= 1.12 % 
 
A similar trend in results obtained from precision studies was observed for Gentiana 
scabra and Gentiana rigescens extracted by refluxing and sonication. Tables 





Quantitation results showed the most dominant phytochemical in all the four Gentiana 
species notwithstanding the method of extraction was gentiopicroside. The highest 
amount of gentiopicroside (4.7 % g/g) was found in the root powder of Gentiana lutea 
extracted by refluxing. This was followed by (1.9 % g/g) found in Gentiana scabra 
also extracted by refluxing. It appeared that the refluxed extracts contained higher 
quantities of phytochemicals than sonicated extracts. A slightly higher amount of 
sweroside (0.0022% g/g) more was found in refluxed Gentiana macrophylla root 
powder when compared to Gentiana lutea extracted by the same method. Finally, the 
highest quantity of swertiamarin (0.8% g/g) was contained in refluxed Gentiana lutea 
root powder as shown in Table 2.10. More details about the quantity of phytochemicals 
in extracts administered to hepatocytes during this study can be found in chapter 3 
which deals with cell work and hepatocyte treatments.  
Table 2.10 Summary Quantitation of Gentiana Spp. Extracted Via Refluxing and 
Sonication (RSD Values in Parenthesis) 
  
 SONICATED G.SPP  REFLUXED G.SPP  
 G. LUTEA Root Powder (%g/g) 
Crude Extract 
(%g/g) Root Powder (%g/g) 
Gentiopicroside 3.7460 (0.52) 10.1185 (0.24) 4.6545 (0.17) 
Sweroside 0.1728 (1.90) 0.8016 (2.0) 0.4050 (1.4) 
Swertiamarin 0.3079 (2.31) 1.3204 (1.0) 0.7580 (0.7) 
G. MACROPHYLLA SONICATED G.SPP REFLUXED G.SPP 
  Root Powder (% g/g) 
Crude Extract 
(%g/g) Root Powder (%g/g) 
Gentiopicroside 0.2804 (0.11) 3.3520 (0.35) 1.5928 (0.2) 
Sweroside 0.0267 (0.17) 0.9080 (1.3) 0.4072 (0.83) 
Swertiamarin 0.0934 (1.5) 0.6001(0.6) 0.2715 (1.7) 
    
G. RIGESCENS SONICATED G.SPP REFLUXED G.SPP 
  Root Powder (% g/g) 
Crude Extract 
(%g/g) Root Powder (%g/g) 
Gentiopicroside 0.2816 (0.8) 0.9001 (0.2) 0.4010 (1.5) 
Sweroside 0.0140 (2.5) 0.0841 (3.8) 0.0331 (2.1) 
Swertiamarin 0.0170 (1.4) 0.0968 (2.01) 0.0427 (0.3) 
G. SCABRA SONICATED G.SPP REFLUXED G.SPP 
  Root Powder (% g/g) 
Crude Extract 
(%g/g) Root Powder (%g/g) 
Gentiopicroside 0.9312 (0.1) 3.6011 (0.27) 1.850 (0.18) 
Sweroside 0.0276 (1.4) 0.7134 (2.3) 0.3270 (1.5) 
Swertiamarin 0.1076 (3.3) 0.9083 (1.8) 0.5030 (3.5) 
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2.5 Discussion 
Performing the HPTLC and RP-HPLC analysis of all Gentian species was a very 
important stage in further validating their authenticity and usefulness in carrying out 
the remaining experiments on cells. The confirmation of substantial amounts of 
gentiopicroside, sweroside and swertiamarin in all four Gentiana species tested first 
by HPTLC and then further substantiated by RP-HPLC provided a key point of 
reference and foundation for understanding their varied effects on liver cells as shown 
in Chapters 3 and 4. The quantitation also served as a basis for aligning 
phytochemicals to the hepatocyte protective effects which were observed.   
Methanolic extracts of Gentiana lutea, which were extracted under vacuum and tested 
qualitatively by RP-HPLC-DAD contained gentiopicroside, amarogentin, sweroside, 
swertiamarin, gentisin and gentioside isomers (Szucs, 2002). The quantities of 
gentiopicroside (3.7 %g/g), sweroside (0.2 %g/g) and swertiamarin (0.3 %g/g) 
obtained in sonicated Gentiana lutea were similar to the quantitation range obtained 
by (Mustafa et al., 2015) who also extracted the lutea species via sonication to obtain 
gentiopicroside (1.85–3.97 %g/g), sweroside (0.05–0.35 %g/g) and swertiamarin 
(0.08–0.3 %g/g), making lutea the species with the highest amounts of all three 
phytochemicals. Furthermore, investigations by (Hayta et al., 2011)  on the 
underground parts of wild growing Gentiana curcurita resulted in the identification of 
the presence of three main secoiridoid-glycosides : gentiopicroside which was in 
higher quantities as well as, swertiamarin and sweroside both of which were always 
in lower quantities. In a study to determine the amounts of gentiopicroside and 
swertiamarin in Gentiana macrophylla, Gentiana rigescens and Gentiana scabra all 
extracted via sonication, (Zhao et al., 2004) found swertiamarin (0.17% g/g) in 
Gentiana macrophylla which was close to the 0.1% g/g swertiamarin found for 
sonicated macrophylla species in this study. However, there were slight variations in 
the quantities of gentiopicroside, sweroside and swertiamarin found in rigescens and 
scabra. For instance, the study found a nil (or too low to quantitate) amount of 
swertiamarin in rigescens whereas this investigation found 0.02% g/g swertiamarin in 
the rigescens species.  
These differences could be attributed to the different climate, soil, species and growth 
periods of the plants.  An amount of 0.5g of fourteen different Gentiana macrophylla 
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samples grown in different climatic conditions were extracted in 20 ml of methanol 
for 30 min by (Qi et al., 2012) which upon comparison to the aforementioned research 
quantitated gentiopicroside in a wide range of between 0.04% g/g to 0.78% g/g 
showing the relevance of climate and growth conditions when quantifying Gentiana 
spp. The quantity of gentiopicroside obtained for this study (0.30% g/g) however fell 
within this stipulated range. Dried roots of Gentiana scabra which were extracted by 
sonication contained gentiopicroside (1.1% g/g) and sweroside (0.05% g/g) (Jiang et 
al., 2005). This was comparable with 0.9% g/g and 0.03% g/g for gentiopicroside and 
sweroside respectively obtained in this study. In considering Gentiana plants extracted 
by refluxing, (Carnat et al., 2005), quantified gentiopicroside  (2.8% g/g to 6.2% g/g) 
in naturally dried Gentiana lutea species which corresponded to 4.6% g/g obtained for 
this study. It is noteworthy that the study by Carnat et al., (2005) also highlighted that 
differences in quantities of phytochemicals were caused by different drying methods 
used. The similarities between the earlier stated results and that of this study may be 
due to the use of refluxing extraction in both cases and the fact that Gentiana lutea 
roots which were commercially obtained had been dried naturally as well.   
It was generally observed that extracts obtained by refluxing in this study contained 
higher levels of phytochemicals gentiopicroside, sweroside and swertiamarin 
compared to sonicated extracts. This was also evidenced in the quantities of the afore-
mentioned phytochemicals derived from the earlier stated investigations which 
utilised sonication compared to the quantities derived from investigations which 
applied the refluxing method. Hence, the refluxed extracts were chosen for cell work. 
These were freeze-dried and used for all the tests on liver cells discussed in the follow-
up chapters. Considering both refluxed and sonicated Gentiana species, lutea emerged 
with the highest amounts of gentiopicroside, sweroside and swertiamarin followed by 
scabra, macrophylla and rigescens in descending order. Between (0.21–0.45% g/g) of 
swertiamarin, and up to 9.53% g/g of the most dominant compound gentiopicroside 
was found in different samples of Gentiana lutea plants tested at the same time.    
Other compounds such as amarogentin found in Gentiana are in trace amounts 
(Aberham et al., 2007). It has been reported that methanol, water, ethanol and 
chloroform are ideal solvents for separating iridoid glycosides such as gentiopicroside 
(Giddings, 1983). In this study however, utilising ethyl acetate: methanol: water 
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(10:2:1) in HPTLC of Gentian spp. elucidated gentiopicroside, sweroside and 
swertiamarin. Gentiopicroside bands obtained in all four Gentiana species had an RF 
value of 0.51. This was similar to an Rf value range of 0.55-0.56 obtained for 
gentiopicroside identified in Gentiana lutea via HPTLC (Camelia et al., 2008). 
Furthermore, a mobile phase of methanol/water 82:18 used under HPLC isocratic 
conditions, for the quantitative study yielded a dominant peak representing 
gentiopicroside, however there were inconspicuous peaks seen for sweroside, 
swertiamarin and xanthone glycosides as seen in typical chromatograms of the 
Gentiana species extracted via sonication but analysed in a gradient HPLC. Using 
methanol/water under gradient conditions described in the methodology a wider 
spectrum of peaks was observed and hence that method was implemented in 
proceeding quantitation experiments. A broad spectrum of peaks were observed for 
the extraction of Gentiana lutea under gradient conditions with mobile phase 
composed of 0.085% (v/v) of phosphoric acid in water and acetonitrile (Aberham et 
al., 2011).  
After verifying the presence of gentiopicroside, sweroside, and swertiamarin in the 
four Gentiana species tested and gaining a preliminary profile of the quantities of 
gentiopicroside, sweroside and swertiamarin phytochemicals in them, the next step 
entailed testing the extracts to determine their effects on liver cells, factoring in the 




This study achieved the aim of employing sonication and refluxing extraction 
techniques to extract the four Gentiana species, after which high performance liquid 
chromatography (HPLC) and high performance thin layer chromatography (HPTLC) 
were used to qualitatively and quantitatively assess three of the inherent 
phytochemicals. The identified and quantified phytochemicals were gentiopicroside, 
sweroside and swertiamarin. After satisfying the aim of this chapter, the next step was 
to test, first the whole plant extracts followed by the individual phytochemicals 
identified on liver cells exposed to fatty acids to determine whether or not they 















Chapter 3. Influence of Gentiana Spp. Extracts on 
Cell Viability of Hepatocytes Treated with 
Lipid (arachidonic acid) 
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3.1 Introduction  
An understanding of the effects of exposing hepatocytes to fatty acids such as 
decreased ATP production, lipid peroxidation and deceased cell viability are key to 
deciphering any possible interventions caused by Gentiana plant extract treatment. 
Fatty acids (FA) play a pivotal role in intracellular signaling and form an important 
component of ligands which bind onto nuclear receptors making them crucial for cell 
viability (Chawla et al., 2001). This chapter examines the outcomes of pre-treating 
hepatocytes with Gentiana spp. extracts before fatty acid exposure, co-administering 
fatty acids and Gentiana spp. extracts to hepatocytes and finally, pre-treating 
hepatocytes with fatty acids before the administration of Gentiana spp. extracts. These 
outcomes were assessed via trypan blue assay, LDH assay, MTT assays and analysed 
via statistical methods setting a precedent for detailed mitochondrial stress, ATP 
production, apoptosis and ROS studies carried out in chapter 4.   
Studying fatty acid uptake is crucial in understanding steatosis, which is a prominent 
feature of non-alcoholic fatty liver disease (NAFLD). The increase in serum-free fatty 
acids causes a rise in hepatocyte fatty acid uptake in excess of metabolic requirements. 
This leads to excessive storage of triglycerides resulting in steatosis and provides a 
substrate for lipid peroxidation (Bradbury, 2006).  
Fatty acids such as arachidonic acid, palmitic acid and oleic acid decrease 
mitochondrial function by uncoupling oxidative phosphorylation (Schönfeld and 
Wojtczak, 2008). Arachidonic acid and palmitic acid have effectively disrupted 
mitochondrial membrane potential after 24 h exposure to hepatocytes (VA-13 cells) 
with arachidonic acid causing a greater degree of mitochondrial membrane potential 
disruption (Gyamfi, 2012). Rat hepatoma cells exposed to oleic, palmitic and 
arachidonic acid caused reduced cellular mitochondrial function with the highest 
damage being recorded in the presence of arachidonic acid (López-Gómez et al., 
1993).  Arachidonic acid caused more disruption in bovine heart mitochondrial 
function compared to palmitic acid (Cocco et al., 1999).  Ethanol and arachidonic acid 
are toxic to HepG2 cells which express CYP2E1 (Chen et al., 1998). Hence 
arachidonic acid was found to be most instrumental in eliciting not only cytotoxicity 
in hepatocytes but also increasing ROS production which is a key factor in NAFLD 
assessed in subsequent chapters.  
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As shown in Fig 3.1, after crossing the hepatocyte membrane, lipoproteins are 
converted by the liver to VLDL and LDL which transports triglycerides back into the 
blood and adipose tissue whereas other lipids undergo β-oxidation to produce energy. 
Triglycerides stored in adipose tissue are hydrolysed to free fatty acids (FFAs) and 
glycerol via a hormone sensitive lipase and transported back into the liver. Some of 
the FFAs from the adipose tissue are re-esterified to triglyceride in the adipose tissue 
whereas others are converted to triglycerides in the liver. Increase in mitochondrial β 
and ɷ-oxidation as well as peroxisomal β-oxidation in a normal liver leads to energy 
production whereas a decrease in oxidation in a fatty liver resulting from 
mitochondrial dysfunction may lead to an increase in unoxidized fatty acids (Reshef 
et al., 2003), (Zechner et al., 2005). Carnitine palmitoyl transferase I (CPT1) catalyses 
the entry of activated fatty acids into the mitochondria of hepatocytes by attaching 
carnitine to fatty acids to enable them to cross the mitochondrial membrane. Once 
inside the mitochondria, fatty acids are detached into the β-oxidation cycle leading to 
the generation of acetyl coenzyme A molecules and hence ATP generation (Dunning 
et al., 2010).    
The accumulation of lipid in the liver can also be the end result of high fat intake 
culminated with reduced energy combustion which is mediated by the mitochondria 
via peroxisome proliferator-activated receptor (PPAR)-α and peroxisomal fatty acid 
β-oxidation Fig 3.1. A dysfunctional or under-functioning cellular mitochondria may 
have a bearing on the level of fatty acids accumulated in liver cells by affecting PPAR-
α,  which functions as a lipid sensor, resulting in diminished fatty acid metabolism, 
hepatic steatosis and steatohepatitis (Reddy and Rao, 2006). Furthermore, the 
accumulation of fatty acids in the mitochondria beyond cellular metabolic capacity 
leads to the production high amounts of reactive oxygen species eventually causing 
lipid peroxidation (Schrauwen and Hesselink, 2004). All these factors have a bearing 
on the cell viability of hepatocytes. The studies in this chapter investigated the capacity 
of Gentiana spp. extracts to preserve the viability of hepatocytes in the presence of 














Fig 3.1. Fatty acid metabolism. Schematic showing the metabolism of fatty acids prior 
to entering the liver. Triglycerides stored in adipose tissue are hydrolysed to free fatty 
acids (FFAs) and glycerol via a hormone sensitive lipase and transported into the 
liver. Increase in mitochondrial β and ώ-oxidation as well as peroxisomal β-oxidation 
in a normal liver leads to energy production whereas a decrease in oxidation in a fatty 
liver resulting from mitochondrial dysfunction may lead to an increase in unoxidized 
fatty acids eventually diminishing liver function (Reshef et al., 2003), (Zechner et al., 
2005)  
NORMAL LIVER FATTY LIVER 
PPAR-α receptor effective 
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The trypan blue technique for determining cell viability has been found to be more 
widely used and safer when compared to the use of eosin and acrylic which are toxic 
to cells when used to determine cell viability (Altman et al., 1993). Both LDH assay 
and MTT assay are effective ways of assessing the viability of cells, however a 
comparison of the two methods showed MTT assay as being more accurate and 
reliable in determining the viability of cells (Fotakis and Timbrell, 2006). 
Notwithstanding the merits and demerits of each of the above-listed cell viability assay 
methods, all of them were assessed in this study to deepen understanding of the 
cytotoxicity of lipids on hepatocytes, optimise the experimental methods and aid in 
practical research skill development.   
 
Mitochondrial dehydrogenase plays an active role in the β-oxidation of fatty acids by 
dehydrogenating long-chain fatty acids to produce a trans double bond between c2 and 
c3. A properly functioning mitochondrion contains active mitochondrial 
dehydrogenases which convert yellow (3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide) (MTT) into purple coloured formazan (Berg et al., 
1990). This assay was used to validate the viability of hepatocytes in the presence of 
fatty acids and Gentiana spp. extracts. In subsequent chapters, cellular condition was 
further assessed to determine whether cells were necrotic, apoptotic or viable. 
Arachidonic acid was the fatty acid of choice for determining the level by which 
Gentiana spp. guard against fatty acid induced cytotoxicity because studies have 
shown that ROS production was significantly increased in hepatocytes (HepG2) with 
arachidonic acid exhibiting a greater effect than palmitic acid  
As per reviewed literature on the interaction of Gentiana spp. extracts with hepatocytes 
exposed to fatty acids, gentiopicroside which can be found in Gentiana spp. 
significantly lowered liver lipid peroxidation in mice caused by tetrachloromethane 
(Yuan, 2015). Gentiana scabra root extracts exhibited anti-lipid peroxidation and 
superoxide radical scavenging activities with IC50 values of 45.8, 183.4, and 56.3 
μg/mL, respectively (Ko et al., 2011). Gentiana macrophylla root extracts showed 
strong 2,2-diphenyl-1-picrylhydrazyl (DPPH) and hydroxyl radical scavenging 
activity (Yu et al., 2004). Furthermore, methanolic extracts of Gentiana lutea roots 
have been found to enhance hepatocyte viability by scavenging superoxide anion, 
hydroxyl radical and hydrogen peroxide responsible for many cell disorders through 
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their action on lipids (Kusšar et al., 2006). Bearing these information in mind, the first 
step in this study was to determine the effects of the Gentiana spp. extracts alone on 
the hepatocytes followed by arachidonic acid alone and then assess how the extracts 




This work aimed at assessing the cytotoxicity of arachidonic acid (10, 30 and 80 μM) 
in VA-13, HepG2 and THLE-2 cell lines in the presence of Gentiana spp (lutea, 
macrophylla, scabra and rigescens) pre-treatment, co-administration and post-
treatment. The extracts used were ones obtained by refluxing as described in Chapter 
2.  
3.3 Materials and Methods 
3.3.1 Cell Line, Cell Culture and Passaging 
 The cell lines used for this study were VA-13 cells (Hep G2 cells that efficiently 
express alcohol dehydrogenase), human hepatocellular (HepG2) cells and THLE-2 
cells. The THLE-2 cells were obtained from (ATTC, UK) whereas VA-13 and HepG2 
cells were obtained from (Dan Clement, University of Nebraska). VA-13 and HepG2 
were cultured in Dulbecco’s modified eagle media (DMEM) with 4 g/L glucose 
(Lonza, Slough, UK) supplemented with foetal bovine serum (FBS) 10 % (Biosera, 
Sussex, UK), sodium pyruvate 1 % (Sigma-Aldrich, UK), L-glutamine 1 % (Sigma-
Aldrich, UK), and penicillin-streptomycin 1% (BioWest, USA). THLE-2 cells were 
cultured in bronchial epithelial growth medium (BEGM) (Lonza, UK) supplemented 
with epidermal growth factor (EGF) 20 µg/mL (Sigma-Aldrich, UK), 
phosphoethanolamine 2.5mg/mL (Sigma-Aldrich, UK) and foetal bovine serum 10 % 
(FBS) (Biosera, Sussex, UK). When thawing cells from liquid nitrogen, vials were 
quickly defrosted at 37 °C in a water bath containing distilled water, washed in 5 mL 
of DMEM containing foetal bovine serum (FBS) 10 % and seeded in to suitable culture 
flask. Prior to seeding of THLE-2 cells flasks were coated for 24 h with a coat 
consisting of 0.1% FBS, collagen 5mg/mL (ATTC, UK) and fibronectin 1 mg/mL 
(Sigma-Aldrich, UK). All cells were maintained in a 37°C incubator (Binder APT 
Germany), and media changes made every three days or earlier if needed. DMEM with 
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1 g/L glucose (Lonza, Slough, UK) supplemented with 1% FBS was used during each 
assay. When the cells reach the required confluency (70-80%) they were passaged or 
frozen for storage. During passage, cells were washed once with Dulbecco’s 
phosphate buffered saline (DPBS) free from calcium and magnesium (Sigma-Aldrich, 
UK), trypsinised with trypsin 0.25% (1X) solution, with 0.1% EDTA (Thermo 
Scientific, UK) and neutralised with DMEM containing FBS 10%. Cells were 
centrifuged at 500 rpm for 5 min, re-suspended in DMEM containing FBS 10 % and 
seeded into a new flask. When freezing cells, they were re-suspended in DMEM 
containing DMSO 10% and kept at -80°C for 24 h prior to storage in liquid nitrogen. 
3.3.2 Method Optimization - Determination of Cell Viability and Cytotoxicity in the 
Presence of Arachidonic Acid 
3.3.2.1 Trypan Blue Exclusion Assay 
VA-13 cells were seeded onto 12-well plates at a concentration of 2.5x105 mL DMEM 
per well for 24 h. The media was discarded, and cells treated with various 
concentrations of arachidonic acid (AA, 20, 40 and 80 μM) and Gentian spp (0.001, 
0.01 and 0.1 μg/mL), i.e. co-administration. Cells were then incubated for 24 h at 
37°C. After treatment, the media was removed from cells in the presence of FCS 1% 
into respective labelled tubes, washed once with PBS and trypsinized. Media and cells 
were centrifuged at 2000 rpm for 5 min, re-suspended in 1 mL of PBS and cells treated 
with 0.1 mL of 0.05% trypan blue for 5 min. Excluded or stained cells were counted 
in a haemocytometer under a light microscope and viability expressed as: [Staining 
total/ (Staining total + Excluding total)] x 100%      
3.3.2.2 LDH Assay 
VA-13 cells were seeded onto 96-well plates at a concentration of 2.5x104 μL DMEM 
per well for 24 h. The media was discarded, and cells treated with 40 μM AA with 1% 
FBS DMEM. The cells were incubated for a period 24 h after which they were 
centrifuged at 250 x g for 4 min to pellet cells. Media was then removed into respective 
Eppendorf tubes. To the cells, LDH assay lysis solution 40 μL was added and 
incubated at 37°C for 45 min. The plates were centrifuged at 250 g for 4 min and 
supernatants (lysates) collected and diluted (1:10) i.e. 20 μL lysate + 180 μL 
PBS/DH2O. A total of 50 μL of supernatants (media and lysates) was transferred to a 
new 96-well flat bottom plate and lactate dehydrogenase assay mixture prepared by 
 68 
mixing equal amounts of LDH assay substrate, cofactor and dye solutions. Assay 
mixture (100 μL) was added to each sample and mixed by shaking for 10s. The plate 
was covered with aluminium foil to protect from light and incubated at room 
temperature for 20-30 min. Absorbance was spectrophotometrically measured at a 
wavelength of 490 nm whereas background absorbance of multi-well plates were 
measured at 650 nm and subtracted from the primary wavelength measurement. 
Percentage LDH released was measured as follows: [(LDH media (A))/ (LDH media 
(A)+LDH lysate (B))] where media (A) was the media removed from the cells prior 
to LDH assay and media (B) includes lysates. 
 3.3.3 MTT Assay for Measuring Cell Viability in the Presence of Arachidonic Acid 
and Gentian spp 
HepG2 cells were trypsinized and seeded at a concentration of 25x103 /200 μL DMEM 
per well for 24 h. The media was then removed, and three different types of treatment 
applied. MTT assay was performed after 24 h by removing treatments/media and 
replacing with 90 μL of media. Thiazole blue tetrazolium bromide (TBT) (Sigma-
Aldrich, UK) 10 μL containing 5 mg/mL TBT in PBS was added per well and 
incubated at 37°C for 2 h. This was removed and then DMSO 50 μL added per well. 
The plates were read at 550 nm after being incubated at room temperature for 15 min. 
MTT assay was used extensively due to its accuracy and minimalization of human 
error. Cell viability/growth was presented as a percentage of control cells with DMSO. 
3.3.3.1 Co-administration MTT Assay 
Cells were treated with 0.01 mg/mL Gentiana species, alongside AA (10, 30 and 80 
μM) and incubated at 37°C (Binder APT.line) for 24 h after which MTT assay was 
performed as previously described in section 3.3.3. 
 
3.3.3.2 Pre-treatment MTT Assay 
Cells were pre-treated with 0.01 mg/mL Gentiana species and incubated at 37°C 
(Binder APT) for 24 h and then treatment removed and replaced with (10, 30 and 80 
μM) arachidonic acid and incubated again for 24 h at 37°C followed by MTT assay.     
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3.3.3.3 Post-treatment MTT Assay 
Cells were pre-treated with arachidonic acid (10, 30 and 80 μM) and incubated at 37°C 
(Binder APT.line) for 24 h and then treatment removed and replaced with (GL, GM, 
GR, GS) 0.01 mg/mL. This was incubated again for 24 h at 37°C and then assayed by 
MTT. 
 
3.3.3.4 Timeline Post-treatment MTT Assay 
Cells were treated with 30 μM AA at 0 h, and then given subsequent treatment of GL 
and GM at different time intervals: 2, 4, 8 and 24 h. One set of control cells had AA 
replaced with media at the above stated hours. MTT assay was performed at the end 
of the timeline period. 
 
3.3.3.5 Timeline Cell Viability Enhancement Experiment  
Cells were treated with GL, GM, GR and GS, 0.01 mg/mL at 0 h, and treatments 
replaced with media at different time intervals: 2, 4, 8 and 24 h. After applying the 
above treatments for the designated hours, the treatments were removed and replaced 




Results refer to mean ± standard deviation and are average values from three to seven 
values per experiment; which were also repeated at least thrice. In order to evaluate 
arachidonic acid toxicity or hepatocyte protection conferred by Gentiana spp. 
comparison among experimental groups was performed via the unpaired t test with 
Welch’s correction, one-way ANOVA with Dunnett’s multiple comparison test and 
finally two-way ANOVA respectively based on the experimental design. Differences 




3.4.1 Cytotoxicity of Arachidonic Acid on Hepatocytes  
In order to determine the level of AA (Arachidonic Acid) cytotoxicity on VA-13 and 
HepG2 cells, trypan blue assay, LDH and MTT assays were performed. VA-13 cells 
actively secrete alcohol dehydrogenase and are more adapted for the investigation of 
ALD. HepG2 cells do not secrete alcohol dehydrogenase and are more suitable for 
NAFLD studies. Due to this, HepG2 cells were more widely used for this study 
(Clemens, 1998). Furthermore, MTT assay was more widely used because it was 
economically viable and also minimised human error. LDH assay of VA-13 cells 
treated with 40 μM AA showed percentage LDH release 90-98% whereas control cells 
showed LDH release of 9-10% (Fig 3.2). Percentage viability of VA-13 cells treated 
with AA (20, 40, and 80 μM) decreased with increase in AA dosage after being 
assayed via trypan blue assay (Fig. 3.3). The lowest percentage viability of 18% was 
recorded for 80 μM AA whereas the highest percentage viability of 77.7% was 
observed for 20 μM AA. Following similar trend MTT assay of hepatocytes treated 
with AA (10, 30 and 80 μM) showed significant decrease in viability compared with 
control cells without any AA exposure (Fig 3.4). The lowest viability of 39.5% was 
recorded for hepatocytes treated with 80 μM AA whereas the highest viability of 
63.3% was recorded for 10 μM AA in line with previous observations for both LDH 
and trypan blue assays.   
 
Fig. 3.2.Cytotoxicity effect of Arachidonic Acid (AA) on hepatocytes. Percentage LDH 
released by VA-13 cells treated with AA 40 μM: 90-98% whereas control cells showed 
LDH release of 9-10%. Lower LDH release represented higher cell viability. Data 
analysed by unpaired t test with Welch’s correction and data shown as mean ± SEM, 





Fig. 3.3. Cytotoxicity of AA on hepatocytes. Trypan blue assay showed cytotoxicity of 
AA increased with increasing concentration of AA. HepG2 cells treated with AA (20, 40 
and 80 μM) produced viabilities with statistically significant mean (one-way anova, 
Dunette’s multiple comparison test) differences compared to control ***p<0.05 .  
 
 
Fig. 3.4. Cytotoxicity of AA on hepatocytes. MTT assay showed cytotoxicity of AA in 
HepG2 cells increasing with increase in dose of AA. HepG2 cells treated with AA (10, 
30 and 80 μM) produced viabilities with statistically significant mean (one-way ANOVA, 








3.4.2 Assessment of Gentian Spp Effect on Hepatocytes (HepG2) 
The level by which Gentian spp enhanced the viability and growth of HepG2 
cells in a dose-dependent manner was assessed by treating HepG2 cells seeded 
at 25x103 /200 μL DMEM per well with GL, GM, GR and GS (0.01 and 0.001 
mg/mL) for 24 h followed by an MTT assay. A timeline assessment of cell 
viability enhancement by the four Gentian was performed by treating HepG2 
cells seeded at 25x103 /200 μL DMEM per well with GL, GM, GR and GS and 
then replacing treatment with media at time intervals 2, 4, 8 and 24 h. It was 
observed that the cell viability increased from 2-24h in the presence of Gentiana 
treatments (Fig. 3.5). The highest percentage cell growth as well as mitogenic 
characteristic was observed in cells treated with GM with 146 % after 24 h. This 
was followed by GR with 142 % after 24 h.  It was generally observed that 
decreasing treatment dose from 0.01-0.001 mg/mL reduced cell viability across 
all species of Gentiana. Other control cells treated with DMEM containing 0.01 
and 0.001 % DMSO presented cell viabilities of 101 % and 103 % respectively.  
It was observed that hepatocytes treated with GM (0.01 mg/mL) showed the 
highest percentage viability of 141% (i.e. 41% increase compared to control cells 
with only media and no treatment); hence portraying a degree of mitogenicity. 







Fig. 3.5. HepG2 cell growth enhancement by Gentian spp timeline. HepG2 cells were incubated in 
media containing GL, GM, GR and GS (0.01 mg/mL) for varying periods of 2-24 h. After treatments, 
cell growth was assessed by MTT assay. Results presented as mean±SD (two-way ANOVA). Gentian 


























Fig. 3.6. HepG2 cell growth enhancement by Gentiana spp. MTT assay showed increase in cell growth 
alongside increase in dose of Gentian from 0.01-0.001 mg/mL. HepG2 cells treated with GL, GM, GR 
and GS (0.01 and 0.001 mg/mL) produced viabilities with statistically significant mean (one-way 
anova) differences compared to control *p<0.05 and **p=0.0029. Percentage viabilities ranged 
between (103-142 %) with the highest viability shown in Gentiana macrophylla    
















































































































































































3.4.3 Effects of Concurrent Exposure of Gentian spp and Fatty Acids to Hepatocytes 
In order to investigate cell viability and also determine whether or not Gentiana spp 
inhibits AA cytotoxicity upon concurrent exposure of both to HepG2 cells; GL, GM, 
GR and GS (0.01 mg/mL) were administered to HepG2 cells in the presence of AA 
(10, 30 and 80 μM) for 24 h. Cytotoxicity as well as percentage cell viability were 
then assessed by MTT assay. Control cells administered with only AA (10, 30 and 80 
μM) for 24 h were also assessed by MTT assay. In the presence of lower AA levels 
(i.e. 10 μM), hepatocytes treated with GM had the highest cell viability of 115 %. 
However, in the presence of higher AA levels (i.e. 30 and 80 μM), GL-treated 
hepatocytes presented with the highest viabilities of 80.5 and 50.9 % respectively. 
There was a general trend of AA cytotoxicity decreasing in the presence of Gentian 
spp particularly at 10 μM AA treatment (Fig 3.7).     
 
 
Fig. 3.7. Cytotoxicity of AA on HepG2 in the presence of Gentian spp. AA cytotoxicity decreased in 
the presence of Gentian spp. GM and GL treated hepatocytes presented the highest viabilities (50.9-
115.4%) in the presence of lower and higher levels of AA (10-80 μM) Data presented as mean±SD Two-
way ANOVA with Tukey Multiple Comparison of Gentian spp treatment factor and control (*p<0.05) 














































3.4.4 Effects of Gentiana spp. on Fatty Acid Pre-treated Cells  
The amount by which Gentiana spp. sustain growth or reverse AA cytotoxicity in 
hepatocytes previously exposed to AA for 24 h was investigated by treating hepG2 
cells with AA (10, 30 and 80 μM) for 24 h. After that period, media containing AA 
treatment was removed and replaced with media containing GL, GM, GR and GS 
(0.01 mg/mL) for 24 h. MTT assay was undertaken after the 24 h incubation period to 
determine percentage cell viability after these two treatments. In this instance, GM 
treated hepG2 cells constantly presented the highest percentage cell viability of (60.7-
96.8%) across all the three AA concentrations used. As observed in the previous 
Gentiana spp. concurrent and pre-treatment experiments, in this case also, cell viability 
in hepatocytes having Gentiana spp. treatment was better than hepatocytes without 
any treatment (Fig 3.8.). Furthermore, GL-treated hepatocytes had the second highest 
percentage viability of (41-76%) across all AA treatments. In the time course 
experiment, hepG2 cells were pre-treated with AA (30 μM) and treatment replaced 
with GL and GM (0.01 mg/mL) at 2, 4, 12 and 24 h respectively. Cell viability was 
then analysed by MTT assay. Cytotoxicity in Gentian-treated hepatocytes decreased 
for both GM and GL treated hepatocytes. GM-treated hepatocytes presented the 












































Fig. 3.8. Cell viability of fatty acid pre-treated cells followed by Gentiana spp treatment. Cell viability 
of HepG2 cells exposed to AA (10, 30 and 80 μM) for 24 h before Gentian spp treatment. Cytotoxicity 
in Gentian-treated hepatocytes decreased for all concentrations of AA used. GM-treated hepatocytes 
presented the highest viabilities (60.7-96.8%) in the presence of lower and higher levels of AA (10-80 
μM) Data presented as mean±SD (Two-way ANOVA with Tukey Multiple Comparison of Gentian spp 
treatment factor and control (*p<0.05) (****p=0.0001) 
 
 
Fig. 3.9. Time course cell viability of HepG2 cells pre-treated with AA and then GL or GM. 
Cytotoxicity in Gentian-treated hepatocytes from 2-24 h decreased for both GM and GL treated 
hepatocytes compared to control cells. GM-treated hepatocytes presented the highest viabilities (89-
95%) in the presence of AA (30 μM) Data presented as mean±SD Two-way ANOVA with Tukey Multiple 
Comparison of Gentian spp treatment factor and control (#p=0.02) (**p=0.0048) (***p=0.0008) 
(****p=0.0001) 
3.4.5 Effects of Fatty Acids on Gentian Pre-treated Hepatocytes 
This study aimed to establish whether pre-treating cells with Gentian prior to fatty acid 
treatment conferred a degree of hepatocyte protection to the cells. In order to establish 
this, HepG2 cells were treated with GL, GM, GR and GS (0.01 mg/mL) for 24 h after 
which treatment was replaced with media containing AA (10, 30 and 80 μM) for 
another 24 h. Cell viability was then studied via MTT assay. AA cytotoxicity was 
observed in GM pre-treated hepatocytes with percentage viabilities ranging from 
(81.2-118%). It appeared that hepatocytes pre-treated with Gentian spp fared better in 
viability than untreated hepatocytes which had the lowest cell viabilities of up to 46% 
at the highest AA dose of 80 μM (Fig. 3.10).   
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Fig. 3.10. HepG2 cell protection conferred by Gentian spp pre-treatment for 24 h. For all Gentian 
pre-treated hepatocytes, AA cytotoxicity decreased compared with untreated cells. GM-treated 
hepatocytes presented the highest viabilities (81.2-118%) in the presence of AA (10-80 μM) Data 
presented as mean±SD Two-way ANOVA with Tukey Multiple Comparison of Gentian spp treatment 















































3.4.6 Effects of Fatty Acids on Gentian Pre-treated THLE-2 cells 
The aim of this experiment was to determine the effects of fatty acids on Gentian pre-
treated THLE-2 cells which are hepatocytes transformed with SV40 large T antigen. 
As shown in Fig 3.10, pre-treatment of THLE-2 cells with Gentiana spp generally 
provided hepatocyte protection against cytotoxic effects of arachidonic acid. Cell 
viabilities ranged from 70 to 103 % with the highest viability recorded in Gentiana 
macrophylla, followed by Gentiana lutea, Gentiana scabra and Gentiana rigescens in 
a decreasing order. Control THLE-2 cells which were not primed with Gentiana spp 
extracts had very low viabilities, markedly in the presence of 80 µM AA which 
decreased cell viability up to 38 %. Furthermore the priming of THLE-2 cells with 
Gentiana extracts on its own did not appear to diminish cellular viability with 






Fig. 3.11. Hepatocyte protection conferred on THLE-2 cells by Gentian spp pre-treatment for 24 h. 
For all Gentian pre-treated hepatocytes, AA cytotoxicity decreased compared with untreated cells. GM-
treated hepatocytes presented the highest viabilities (70-103%) in the presence of AA (10-80 μM) Data 
presented as mean±SD Two-way ANOVA with Tukey Multiple Comparison of Gentian spp treatment 






























































The study aimed to investigate hepatocyte protection conferred by four different 
species of Gentiana in a comparative manner to determine the best species in this 
regard. In the optimisation stage of the study trypan blue, LDH and MTT assays were 
performed to primarily to assess in a dose-dependent manner, the level of cytotoxicity 
caused by the treatment of hepatocytes with AA (10-80 μM). The use of trypan blue 
assay to assess cell viability after treatment with 60-80 μM arachidonic acid exposure 
to Jurkat cells indicated in cell viabilities of up to 28% within 24-48 h (Siddiqui et al., 
2001). In this study however, percentage viability of VA-13 cells treated with AA (20, 
40, and 80 μM) decreased with increase in AA dosage after being assayed via trypan 
blue assay. The lowest percentage viability of 18% was recorded for 80 μM AA 
whereas the highest percentage viability of 77.7% was observed for 20 μM AA (Fig 
3.3).  
As shown below in Fig 3.12, the study began by assessing and confirming the 
cytotoxicity of AA on cell lines (VA-13 and HepG2), followed by a study of the effects 
of Gentiana spp. alone on hepatocytes in terms of cell viability. Co-administration of 
Gentiana spp. and AA studies were conducted on hepatocytes after determining that 
Gentiana species enhanced cell viability to a great degree whereas AA showed toxicity 
to hepatocytes.  
 
In order to determine the most effective means to administer Gentiana spp. extracts to 
cells further studies were conducted entailing AA pre-treatment of cells followed by 
Gentiana spp. extracts and then Gentiana spp. pre-treatment followed by AA 
treatment. The study was concluded by using the best treatment regimen i.e. Gentiana 
spp. extract pre-treatment method on THLE-2 cells to determine if cell growth 
enhancement was only limited to HepG2 cells or could be seen in other cell types such 




Fig 3.12. Chronological summary of studies on hepatocytes and outcomes. The 
first point of study was AA cytotoxicity studies aimed at confirming the toxicity of AA 
to hepatocytes followed by studies to investigate the effect of Gentiana spp. on 
hepatocyte cell viability. A comparison was drawn between co-administration of AA 
and Gentiana spp. extracts, AA pre-treatment prior to Gentiana spp. exposure and 
Gentiana spp. pre-treatment prior to AA exposure to determine the most effective 
treatment sequence in terms of hepatocyte viability enhancement. Gentiana spp. pre-
treatment which was the most effective treatment sequence was used to test the effects 
of AA on THLE-2 cells primed with Gentiana spp.  
†CV-Cell viability, GL-Gentiana lutea GM-Gentiana macrophylla, GR-Gentiana rigescens GS- Gentiana scabra    
AA Cytotoxicity
• AA (40 µM 
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3.5.2 Assay of Cytotoxicity of Arachidonic Acid (AA)   
Cytotoxicity in the presence of AA may be attributed to hepatocyte plasma membrane 
rupture and enzyme leakage which allows trypan blue staining to occur hence plasma 
membrane integrity can be assessed via cellular enzyme leakage and its interaction 
with vital dye staining. Exclusion of the vital dye trypan blue by hepatocytes at the 
time of isolation has become a widely accepted method of determining cell viability 
with major laboratories reporting 85-99% absorption of the dye by hepatocytes  
(Jauregui, 1981). Following a similar trend, LDH assay of VA-13 cells treated with 
40 μM AA showed percentage LDH release 90-98 % whereas control cells showed 
LDH release of 9-10 % in Fig 3.1. This signified substantial increase of LDH release 
into the media in the presence of AA 40 μM. The LDH assay indirectly measures the 
number of viable cells either via the total cytoplasmic LDH or the amount of 
cytoplasmic LDH released into the media serving as an index for determining the 
percentage of cell viability (Yang et al., 2008).  
MTT assay of hepatocytes treated with AA (10, 30 and 80 μM) showed significant 
decrease in viability of up to 39.5% compared with control cells without any AA 
treatment. After a 24 h incubation of HepG2 cells with AA, lactate dehydrogenase 
(LDH) release was induced, as well as cytotoxicity and alterations in cell proliferation. 
MTT assay of cells showed a significant decrease in viability up to  37%, p<0.01 
(Holownia et al., 2014). MTT assay was more widely used in this experiment because 
it was economically viable in comparison to the LDH assay and also minimised human 
error more than the trypan blue assay. 
 
3.5.3 Effects of Gentiana spp. on the Viability of HepG2 Cells  
After establishing cytotoxicity of AA via the above methods in a dose-dependent 
manner, the next investigation was aimed at determining the effect of Gentian spp. on 
hepatocytes in a dose-dependent manner.  
Apart from enhancing hepatocyte cell viability in a dose-dependent manner, length of 
treatment time also played a factor in determining the extent of viability conferred. 
Hepatocytes treated with Gentian spp. for the maximum time of 24 h showcased the 
highest percentage viability whereas low figures were recorded for the shortest 
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treatment time of 2 h (Fig. 3.6). This factor contributed to the choice of 24 h in 
investigating the level of arachidonic acid cytotoxicity reduction in the presence of 
Gentian pre-treatment, co-administration and post-treatment. It was observed that cell 
growth was more enhanced in Gentian treated hepatocytes than control hepatocytes 
lacking Gentian treatment.  
A mitogenic effect was observed for Gentiana lutea as well as Gentiana macrophylla. 
Furthermore, percentage cell viability increased with an increase in dose of Gentian 
spp. from 0.001 to 0.01 mg/mL. However, the species which enhanced hepatocyte 
growth the most was GM with an increase of up to 142 (i.e. 42 % more than control 
cells without Gentiana treatment) compared to control cells followed by GR and GL 
with 12-39% increase in cell viability (Fig. 3.5). This observation was in line with 
studies which suggest that Gentiana species: lutea, macrophylla, rigescens, scabra 
manshurica and olivieri protect and enhance hepatocyte viability via their antioxidant, 
anti-inflammatory and bitter components including: amarogentin gentianine, iso-
orientin, swertiamarin, gentiopicroside, and sweroside (Wang et al., 2010b). 
  
 
3.5.4 Pre-treatment, Co-administration and Post-treatment Effects of Gentiana spp 
on Hepatocyte Viability in the Presence of Arachidonic Acid 
Co-administration of Gentian with AA helped to decipher whether or not there was 
any interaction between the plant extracts and the fatty acid, and also whether or not 
that interaction was detrimental to hepatocyte viability. The results obtained appeared 
to show a lack of Gentian-AA interaction, detrimental to hepatocyte cell viability. (Fig 
3.7)  
Having established a lack of detrimental interaction, hepatocytes were then exposed 
to AA prior to Gentian treatment in order to ascertain whether or not the plant extracts 
could contribute in any way to aiding cellular recovery after fatty acid induced 
cytotoxicity. In this instance, the results indicated a degree of enhanced cellular 
recovery in Gentian-treated hepatocytes as compared to control cells which were 
treated with plain media after the AA exposure period.  
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Finally, a test was conducted to establish whether or not pre-treating or priming 
hepatocytes with Gentian before exposing them to AA conferred hepatocyte protection 
against fatty acid induced cytotoxicity. The results expressed Gentian pre-treatment 
provided protection to hepatocytes against fatty acid induced cytotoxicity. (Fig. 3.10) 
It was also noted that even though the lutea species contained the highest proportions 
of gentiopicroside and swertiamarin, among the four species studied, it only had a 
higher viability than macrophylla during co-administration, whereby the extract and 
the arachidonic acid were given at the same time for just 24 h. In all other instances 
during which cells were primed with extract before fatty acid exposure, GM had the 
highest viability. Research by (Balijagić et al., 2012) states that Gentiana lutea 
extracts showed toxicity to HeLa cells at a dose of 41 µg/mL although it is a potent 
hepatoprotective and anti-inflammatory agent. This cytotoxicity was attributed to a 
mixture of secoiridoid glycosides, mangiferin, isogentisin and gentiopicrin. This may 
be one of the reasons why although lutea pre-treated cells had a lower cell viability 
than macrophylla pre-treated cells even though the (10 µg/mL) of lutea administered 
contained the highest gentiopicroside (1.0118 µg/mL) and swertiamarin (0.35 µg/mL). 
Macrophylla on the other hand contained a slightly more sweroside (0.24 µg/mL) than 
lutea but contained a lower amount of gentiopicroside than lutea (0.4330 µg/mL) 
based on quantitation results from Chapter 2. The HPLC chromatograms also showed 
peaks which were not seen in macrophylla for other secoiridoid glycosides which may 
be cytotoxic as mentioned above. Hence, with pre-treatment, cells were exposed to 
lutea and all the other possibly cytotoxic secoiridoid glycosides for up to 48 hours (i.e. 
during the 24 h for drug only treatment, and another 24 h when arachidonic acid is 
administered) before MTT assay hence lower viability compared to macrophylla. In 
the co-administration however, cells were exposed for only 24h (i.e. both extract and 
arachidonic given at the same time for 24 h) followed by MTT hence a lesser exposure 
time to both hepatoprotective and possibly cytotoxic secoiridoid glycosides making 
lutea perform better than macrophylla in that instance.  
 
3.5.5 Viability of THLE-2 Hepatocytes Pre-treated with Gentiana spp Prior to 
Arachidonic Exposure 
Having noted Gentiana spp. pre-treatment as the most effective means of securing 
hepatocyte protection based on the viability data obtained, this same method was 
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applied in testing hepatoprotective effects of Gentiana extracts on THLE-2 cells 
THLE-2 which are liver epithelial cells transformed with SV40 large T antigen 
(ATTC, 2017). This assay was necessary to draw a comparison between the effects of 
Gentiana pre-treatment on HepG2 cells which are replicating liver cells and THLE-2 
cells which are uncancerous liver cells transformed with SV40 large T antigen. The 
results obtained for THLE-2 were consistent with results obtained for HepG2 cells 
with Gentiana macrophylla primed THLE-2 cells presenting the highest viability of 
up to 103 % in the presence of AA. This was not as high as the viability of 118 % 
recorded for Gentiana macrophylla in HepG2 cells. A study found HepG2 cells to 
possess higher sensitivity for basic compounds whereas THLE-2 cells possessed 
higher sensitivity for acidic and neutral compounds (Shah et al., 2014). As seen in Fig 
3.11, the lower cell viability seen in THLE-2 in comparison with HepG2 cells could 
be attributed to their high sensitivity to the effects of arachidonic acid due to its acidity 
causing more damage in the THLE-2 cells than in the cancerous HepG2 cells.  
The hepatoprotective effects of individual phytochemicals: gentiopicroside, sweroside 
and swertiamarin are investigated further in chapter 4. Other studies have shown that 
another plant: Lippia noduflora and silymarin also protected HepG2 cells by reducing 
reactive oxygen species in the presence of hepatotoxins. MTT assay of the HepG2 
cells pre-treated with Lippia noduflora and silymarin showed a decrease in cell death 
by 16 % and 28 % respectively in the presence of hepatotoxins (Arumanayagam and 
Arunmani, 2015). In this study however, hepG2 cell death was decreased by as much 
as 31.8 % and 35.2 % respectively by pre-treating cells with the two best performing 
Gentian spp: lutea and macrophylla prior to AA exposure. Hence this study presents 





This study found the four Gentian spp: lutea, macrophylla, scabra and rigescens as 
hepatocyte protectors and identified the presence of gentiopicroside in all four plants. 
Being the first study of its kind to compare hepatocyte-protective activity of the four-
named species of Gentian, this study discovered Gentiana lutea and Gentiana 
macrophylla as the more dominant hepatocyte protectors among the plants 
investigated. Furthermore, the most effective means of conferring hepatocyte 
protection was by pre-treatment of hepatocytes with Gentiana plants prior to 
arachidonic acid exposure. The next step in this study entailed assays aimed at 
establishing the mode by which the Gentian species protect hepatocytes from fatty 
acid cytotoxicity and the role played individually by the single compounds: 
gentiopicroside, sweroside and swertiamarin in conferring hepatocyte protection. 
From a synergistic point of view, an understanding of the mode by which Gentiana 
phytochemicals protect liver cells and their mechanism of action will set a foundation 
for potential studies on the synergistic effect of using these phytochemicals with other 
well-known hepatocyte protectors such as silymarin or reducdyn (N-acetyl - D, L - 
homocysteine thiolactone). Finally, individual phytochemicals: gentiopicroside 


















Chapter 4. Influence of Lipid (arachidonic acid) on 
Hepatocytes Pre-treated with Single 
Compounds: Gentiopicroside, Sweroside, 
Swertiamarin and Silymarin 
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4.1 Introduction  
In the previous chapter, it was found that all the Gentiana species studied produced a 
degree of hepatocyte protection in terms of maintaining and improving cell viability 
of hepatocytes; most notable among them being G. lutea and G. macrophylla but this 
also raised many questions such as: 
 How may Gentiana spp. extracts enhance cell viability of hepatocytes? 
 Which phytochemicals in the Gentiana spp. extracts may be responsible for this 
cell viability enhancement? 
 Do these phytochemicals work individually or synergistically to promote cell 
viability? 
 Do Gentiana spp. promote hepatocyte protection and cell viability by preventing 
necrosis or apoptosis or both? 
  Is cell viability preserved by the scavenging of reactive oxygen species (ROS) 
produced as a result of exposure to high concentrations of AA? 
 The mitochondria plays an important role in fatty acid metabolism in terms of β-
oxidation. Do Gentiana spp. extracts enhance mitochondrial function and capacity 
in any way? Especially in terms managing mitochondrial stress caused by high 
energy demand or high influx of arachidonic acid. 
 Do Gentiana spp. extracts and phytochemicals affect the amount of ATP produced 
by hepatocytes, hence having a bearing on cellular metabolic rate 
 Do Gentiana spp. extracts and phytochemicals affect cellular respiration in terms 
of oxygen consumption rate? And is that a mechanism for protecting liver cells 
and promoting cell viability observed in Chapter 3?  
In order to answer these questions, this chapter further looks into the Gentiana species 
in terms of its phytochemicals gentiopicroside, sweroside (Fig. 4.1) and swertiamarin 
(Fig. 4.2) with the aim of determining if they play any role in providing protection to 
hepatocytes by first determining their individual effects on hepatocyte (HepG2 and 
THLE-2) cell viability via MTT. This was followed by a sequence of assays including 
the seahorse mitochondrial stress assay with focus on hepatocyte ATP production, 
non-mitochondrial respiration, proton leak, basal respiration, maximal respiration and 
spare respiratory capacity, in the presence of oligomycin, FCCP, antimycin and 
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rotenone. This was then followed by DCF ROS assay and annexin V-FITC apoptosis 
flow cytometric assay.  
These phytochemicals were studied jointly with silymarin which is a well-known 
hepatoprotective phytochemical derived from milk thistle (Silybum marianum). 
Silymarin (Fig 4.1) has been shown to possess antioxidant and hepatoprotective 
protective properties (Saller et al., 2001). Studies in rat modules have shown that 
silymarin promotes mitochondrial function by inhibiting lipid peroxide formation in 
the mitochondria of rat livers and microsomes (Bindoli et al., 1977). Silymarin may 
act by supressing TNF-α activation of NF-κB dependent transcription as well as p50 
and p65 nuclear translocation (Polyak et al., 2010). Hepatocellular parameters such as 
mitochondrial ATP content, respiratory control ratio and glutathione were improved 
in the presence of silymarin (Ligeret et al., 2008). Silymarin is well adopted for studies 
involving a wide range of toxic models and provides hepatoprotective effects via 
mechanisms such as: anti-lipid peroxidation, anti-fibrosis, anti-inflammation, 
providing membrane stability, immunomodulation and being an antioxidant (Pradhan 
and Girish, 2006). These studies projected silymarin as the best phytochemical for 
comparing gentiopicroside, swertiamarin and sweroside hepatoprotective effects via 
MTT assay, seahorse mitochondrial stress assay and DCF ROS assay to investigate 
reactive oxygen species scavenging effects of the Gentiana phytochemicals.  
Studies have shown that gentiopicroside, sweroside and swertiamarin shown in  Fig 
4.1 were responsible for hepatoprotective effects exerted by Gentiana manshurica as 
well as Gentiana turkestanerum against carbon tetrachloride induced hepatic damage 
in mice (Zhu and Chen, 2007) (Yang et al., 2017). Gentiopicroside, sweroside and 
swertiamarin found in Gentiana scabra exerted hepatoprotective effects on 
hepatocytes by diminishing oxidative stress (Ko et al., 2011). In a rat liver damage 
model induced by α-naphthylisot hiocyanate, swertiamarin at a dose of  20 mg/kg 
portrayed hepatoprotective effects by significantly reducing alanine aminotransferase, 
aspartate aminotransferase and the total and direct bilirubin levels which had been 
increased in the presence of α-naphthylisot hiocyanate while conversely increasing 












Fig 4.1 Structures of Gentiana phytochemicals. Chemical structures of 
phytochemicals: (A) sweroside, (B) swertiamarin, (C)gentiopicroside and (D) 
silymarin  
 
The seahorse mito stress assay is a useful tool for assessing cellular mitochondrial 
stress resulting in a more detailed understanding and evaluation of mitochondrial 
dysfunction, signals, phenotypes and metabolic pathway. It performs these by 
measuring cellular oxygen consumption rate (OCR) via a probe in the presence of 
oligomycin which inhibits ATP synthase (complex V), cyanide-4 (trifluoromethoxy) 
phenylhydrazone (FCCP) which uncouples OCR (i.e. affects the inner mitochondria 
by reducing the proton gradient; thereby affecting membrane potential) and then 
antimycin and rotenone A which block complex 1 and III. Fig 4.2 (Luz et al., 2015). 
Exerting these effects on the electron transport chain enables the seahorse mito stress 
assay to measure parameters such as basal respiration (level of OCR required for ATP 
production), ATP production itself, proton leak (can deduce mitochondrial damage or 
ATP production regulation), maximal respiration (highest mitochondrial respiratory 






fitness and ability to respond quickly to energy requirements) and non-mitochondrial 
respiration (accounts for OCR of other cellular enzymes) (Agilant, 2017) (Lay et al., 
2016) These are pictorially illustrated by Fig 4.2 and summarized as follows:  
 Basal Resp. = Basal OCR – Non-Mitochondrial Resp. (Rot & Ant A induced) 
 ATP Prod. = Basal OCR – Oligomycin induced OCR 
 Proton Leak = Oligomycin induced OCR - Non-Mitochondrial Resp. 
 Maximal Resp. = FCCP induced OCR -  Non-Mitochondrial Resp. 
 Spare Resp. Capacity = FCCP induced OCR - Basal OCR 





Fig. 4.2. Seahorse XF cell mitochondrial stress test profile. Oligomycin inhibits 
complex V, FCCP is an uncoupler, rotenone and antimycin inhibits complex I & III 
respectively. Parameters such as basal respiration, ATP production, maximal 
respiration, spare respiratory capacity and non-mitochondrial respiration can be 
measured by the seahorse mito stress assay (Seahorse Bioscience, 2015)  
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The seahorse mito stress assay was used in the presence of oligomycin, FCCP and 
rotenone which are sequentially injected to determine the oxygen consumption rates 
(OCR) of hepatocytes in a study on the effect of caspase-1 activity on hepatocyte 
protection after oxidative stress (Sun et al., 2013b). Mitochondrial proton leakage and 
OCR of  were measured by the seahorse mito stress assay in studies investigating the 
link between oxidative stress, mitochondrial dysfunction and obesity (Li et al., 2010). 
In deciphering the effect of BNip3 (an apoptotic Bcl-2 protein) in regulating 
mitochondrial function and lipid metabolism in THLE-2 cells, the seahorse mito stress 
assay was used to detect increased hepatocellular respiration in the study which 
concluded that the role of BNip3 in diminishing mitochondrial mass while retaining 
mitochondrial integrity had key consequences for lipid metabolism in hepatocytes 
(Glick et al., 2012). It has been confirmed independently that at the time of submitting 
this thesis, this was the first study which used the Seahorse mito stress assay to assess 
the four Gentiana species and phytochemicals. 
ROS are generated continuously during hepatocellular anaerobic metabolism and 
plays a key protective and functional role in hepatocytes. An increase in ROS above 
the ROS scavenging threshold of hepatocytes can be detrimental to the viability of 
hepatocytes. The dichlorohydrofluorescein diacetate (DCF-DA) ROS assay is highly 
sensitive employs a cell permeability fluorescent chemiluminescent probe to measure 
hepatocellular redox (Eruslanov and Kusmartsev, 2010). This assay was used to 
determine whether or not phytochemicals in Gentiana spp extracts preserved cell 
viability by preventing the accumulation of reactive oxygen species. The DCF-DA 
ROS assay was chosen due to its high sensitivity, wide usage and ability to offer real-
time monitoring of ROS changes in hepatocytes. By using the  DCF-DA ROS assay 
(Huang et al., 2008) demonstrated that oridonin stimulated hepatocyte (HepG2) 
mitochondrial transmembrane permeability in a ROS-dependent mechanism. 
Furthermore, mitochondrial mediated apoptosis triggered by ROS in hepatocytes 
(HepG2) cells was studied using DCF-DA ROS assay (Sharma et al., 2012). ROS 
production triggered by tert-butyl hydroxyperoxide was found to be significantly 
reduced in the presence of  10 μM quercetin after conducting the DCF-DA ROS assay 
(Alía et al., 2006). 
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Apoptosis is a programmed and controlled cell death which is pre-programmed as part 
of a cell’s life cycle. Morphological transformations including nuclear condensation, 
cell surface changes, cell shrinkage and DNA transformation culminating in apoptosis 
(Andree et al., 1990). Annexin V is a calcium-dependent, phospholipid-binding 
protein which selectively binds to phosphatidylserine. This assay is useful in 
determining apoptosis based on the assertion that mammalian cells relocate 
phosphatidylserine from the inner face of the plasma membrane to the cell surface as 
soon as apoptosis is triggered putting annexin V in a position selectively bind to the 
released phosphatidylserine (Zhang et al., 1997). Using the annexin V-FITC assay to 
determine whether or not phytochemicals in Gentiana spp. prevented apoptosis was 
key to determining if the enhanced cell viability observed in chapter 3 was as a result 
of promoted cell longevity via a slowdown or prevention of the apoptotic process in 
hepatocytes.  Studies have shown that arachidonic acid causes apoptosis by producing 
cytosolic phospholipase A2 eventually causing mitochondrial permeability transition 
(Scorrano et al., 2001). Annexin V-FITC was used to determine the anti-apoptotic 
properties of Fumaria parviflora against nimesulide induced apoptosis in hepatocytes 
(Tripathi et al., 2010). 
In summary, the workflow of this chapter entailed an initial determination of the 
ability of the phytochemicals: gentiopicroside, sweroside and swertiamarin to enhance 
hepatocyte viability in the presence of arachidonic and minimise its cytotoxicity.  After 
all these assays, the best performing phytochemical was further analysed in 
comparison with the best performing whole plant extracts via annexin V-FTIC 
apoptosis test with flow cytometry and MTT to serve as a foundation for potentiation 
studies and further deepen understanding into their mechanism of action.   
4.2 Aim 
This chapter aimed to investigate whether or not the enhanced cell viability 
demonstrated by the Gentiana spp. extracts in Chapter 3 could be attributed to inherent 
phytochemicals and if their effects were synergistic in nature. The mechanism by 
which phytochemicals in Gentiana spp. extracts conferred hepatocyte protection via 
cell viability enhancement was also studied in this chapter.  
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4.3 Materials and Methods   
4.3.1 Cell Line, Cell Culture and Passaging 
For this study, human hepatocellular (HepG2) cells were utilised. The HepG2 cells 
were obtained from (ATTC, Middlesex UK). All cell lines were cultured in 
Dulbecco’s modified eagle media (DMEM) with 4 g/L glucose (Lonza, Slough, UK) 
supplemented with 10% foetal bovine serum (FBS) (Biosera, Sussex, UK), 1% sodium 
pyruvate (Sigma-Aldrich, UK), 1% l-glutamine (Sigma-Aldrich, UK), and 1% 
penicillin-streptomycin (BioWest, USA). When thawing cells from liquid nitrogen, 
vials were quickly defrosted at 37 °C in a water bath containing distilled water, washed 
in 5 mL of DMEM containing foetal bovine serum (FBS) 10 % and seeded in to 
suitable culture flask. Cells were maintained in a 37°C incubator (Binder APT, 
Germany), and media changes made every three days or earlier if needed. DMEM with 
1 g/L glucose (Lonza, Slough, UK) supplemented with 1% FBS was used during each 
assay. When the cells reach the required confluency (70-80%) they were passaged or 
frozen for storage. During passage, cells were washed once with Dulbecco’s 
phosphate buffered saline (DPBS) free from calcium and magnesium (Sigma-Aldrich, 
UK), trypsinised with trypsin 0.25% (1X) solution, and neutralised with DMEM 
containing FBS 10%. Cells were centrifuged at 500 rpm for 5 min, re-suspended in 
DMEM containing FBS 10 % and seeded in to a new flask. THLE-2 hepatocytes were 
cultured as shown in 3.3.1.  
4.3.2 Single Compounds and Arachidonic Acid Preparation 
Single compounds: gentiopicroside (Abcam, UK), sweroside (Sigma-Aldrich, UK), 
swertiamarin (Sigma-Aldrich, UK), and silymarin (Abcam, UK) were prepared by 
making 8mM stock solutions in DMSO and then diluted with DMEM containing FBS 
10 % as needed to obtain 20 µM final concentration. An 8mM stock of arachidonic 
acid was prepared in DMSO and diluted to 10, 30, 50 and 80 µM with DMEM as per 
the requirements of each assay.  
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4.3.3 MTT Assay for Measuring Cell Viability of cells pre-treated with, Single 
Compounds: Gentiopicroside, Sweroside, and Silymarin in the Presence of 
Arachidonic Acid 
HepG2 cells were trypsinized and seeded at a concentration of 25x103 /200 μL DMEM 
per well for 24 h and kept in an incubator (Binder APT, Germany) at 37°C. The media 
was then removed and three different types of single compound treatments were 
applied. Cells were pre-treated with (gentiopicroside, sweroside or silymarin) 20 µM 
and incubated at 37°C (Binder APT, Germany) for 24 h and then treatment removed 
and replaced with arachidonic acid (10, 30, 50 and 80 μM) and incubated again for 
37°C and then assayed via MTT as described earlier in section 3.2.4. MTT assay was 
also performed to compare the best performing (most hepatoprotective) single 
compound with the best performing plant extract deepen understanding on effects and 
prepare for future potentiation studies.      
4.3.4 Seahorse Assay for Assessing Mitochondrial Function of cells Pre-treated with 
Gentiana species and Single Compounds: Gentiopicroside, Sweroside, 
Swertiamarin and Silymarin in the Presence of Arachidonic Acid 
Seahorse assay was performed seeding HepG2 cells in a seahorse XF24 plates at a 
concentration of 5x103 /250 μL DMEM per well and kept for 24 h in an incubator 
(Binder APT, Germany) at 37°C. Media was removed and cells  pre-treated with single 
compounds: (gentiopicroside, silymarin, swertiamarin or sweroside) 20 µM and 
incubated for another 24 h at 37°C. Media containing treatment was discarded after 
the incubation period and replaced with media containing 30 μM AA and then 
incubated at 37°C for 24h. After incubation, seahorse assay was initiated by removing 
media and washing thrice with 400 μL of seahorse media containing 1 % sodium 
pyruvate and 4.4 g/L glucose and media stabilized at ph 7.4. After washing, 500 μL of 
seahorse media was placed in each well and then incubated in a non-CO2 incubator (to 
minimalize the influence of incubation of conditions) pending completion of 
calibration plate running. The calibration plate was prepared by placing oligomycin (5 
μM), FCCP (5 μM) antimycin and rotenone (5 μM) after which it was placed in the 
seahorse XFe 24 analyser (Aglient/Seahorse Bioscience, USA). After calibration, the 
assay plate was removed from the non-CO2 incubator and placed in the seahorse XFe 
24 machine which measured oxygen consumption rate (OCR) in pmol/min at 
oligomycin, FCCP, antimycin and rotenone injection points. The hepatocytes in the 
plate were normalized after reading via the BCA protein assay. Taking normalisation 
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results, basal respiration, ATP production, proton leak, maximal respiration, spare 
respiratory capacity and non-mitochondrial respiration were calculated as follows 
shown in section 4.1. 
4.3.5 DCF Assay for Assessing ROS Produced by cells Pre-treated with Gentian spp 
and Single Compounds: Gentiopicroside, Sweroside, Swertiamarin and Silymarin 
in the Presence of Arachidonic Acid 
 
HepG2 cells were trypsinized, seeded and treated as earlier explained in 4.3.3. In this 
instance, however, pre-treatment included Gentiana macrophylla (0.01 mg/mL) in 
addition to the single compounds in section 4.2.3. Also, dark clear bottom 96 well 
plates optimized for fluorescence-based application (Thermo Fisher Scientific, UK) 
were utilised. After arachidonic treatment and 24 h incubation at 37°C, DCF assay 
was performed by removing arachidonic acid treatment and washing each well with 
100 µL of 1X buffer supplied with DCFDA-cellular reactive oxygen species detection 
assay kit (Abcam, UK). Prior to the DCF assay, positive control HepG2 cells were 
treated with tert-butyl hydrogen peroxide (TBHP) 50 µM for 2hours. This treatment, 
as well as the 100 µL of 1X buffer were removed and DCFDA assay reagent 100 µL 
of 20 µM added to each well and incubated for 30 min at a temperature of 37°C away 
from light. DCFDA was then removed from each well and replaced with 100 µL of 
1X buffer followed by the measurement of fluorescence with (Fluostar Optima, BMG 
Labtech, UK) at excitation 485 nm and emission 535 nm.     
4.3.6 Annexin V-FITC PI Assay for Investigating Apoptosis in Hepatocytes Pre-
treated with Gentiana macrophylla and Single Compounds: Gentiopicroside, Prior 
to Arachidonic Acid exposure. 
HepG2 cells were trypsinized and seeded in a 12-well plate at a concentration of 
20x104 cells/mL DMEM per well for 24 h and kept in an incubator (Binder APT, 
Germany) at 37°C. The media was then removed after which single compound 
gentiopicroside (20µM) and Gentiana macrophylla (10 µg/mL) pre-treatments were 
applied and incubated at 37°C (Binder APT) for 24 h and then treatment removed and 
replaced with arachidonic acid (30 μM) and incubated again for 24 h. Prior to annexin 
V assay, apoptosis was induced in the positive control group by adding 1µg/mL 
actinomycin whereas the negative control had cells with DMEM without any 
apoptosis inducing agent. Cells were harvested and washed in cold phosphate-buffered 
saline (PBS), recentrifuged and then re-suspended in 100 µL of 1x binding buffer after 
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discarding the supernatant. Annexin V-FITC (5 µL) and propidium iodide (PI) (5 µL) 
from the annexin V-FITC apoptosis detection kit (Stratech, UK) were added to each 
100 µL of cell suspension. The cells were then incubated at room temperature for 15 
minutes followed by the addition of 400 µL of 1x buffer. Flow cytometric 
measurements of the samples at a fluorescence 530 nm (emission) and 575 nm. 
Apoptotic cells showed green fluorescence whereas necrotic cells showed both red 
and green fluorescence.     
4.3.7 Statistics 
Results refer to mean ± standard deviation and are average values from three to seven 
values per experiment; which were also repeated at least thrice. Evaluation of 
hepatocyte protection conferred by single compounds at different concentrations of 
AA was performed via the two-way ANOVA with Tukey multiple comparison test 
(detailed test results in appendix). Differences at p<0.05 were considered significant.     
 
4.4 Results 
4.4.1 A Comparison of the Cytotoxic Effects of Fatty Acid on Single Compounds: 
Gentiopicroside, Sweroside, and Silymarin Pre-treated Hepatocytes (HepG2) 
This experiment investigated whether pre-treating cells with gentiopicroside, 
sweroside and silymarin prior to fatty acid exposure conferred a degree of hepatocyte 
protection to the cells. In order to establish this, HepG2 cells were treated with the 
above-listed compounds (20 μM) for 24 h after which treatment was replaced with 
media containing AA (10, 30, 50 and 80 μM) for another 24 h (Fig 4.3). Cell viability 
was then studied via MTT assay. Consistency in reduced AA cytotoxicity was 
observed in all pre-treated hepatocytes with percentage viabilities ranging from (60-
159%). Hepatocytes pre-treated with gentiopicroside had the highest range of cell 
viability (85-159 %) across all doses of fatty acid exposure compared to untreated 
hepatocytes. This was followed by silymarin with a range of (73-145%) and then 
sweroside with a range of (60 to 135%). Vehicle control cells (Fig. 4.3) which had 
been not exposed to any arachidonic after phytochemical pre-treatment had the highest 
viabilities recorded for each treatment. The lowest cell viability of 28% was recorded 
for hepatocytes exposed to arachidonic acid without any phytochemical pre-treatment. 
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  Fig. 4.3. MTT assay results showing hepatocyte protection conferred by phytochemicals. MTT assay 
results showing hepatocyte protection conferred by gentiopicroside (GP), silymarin (SIL) and 
sweroside (SWER) pre-treatment for 24 h. For all phytochemical pre-treated hepatocytes (hepG2), AA 
cytotoxicity decreased compared with untreated cells. GP-treated hepatocytes presented the highest 
viabilities (85-159 %) in the presence of AA (10-80 μM) Two-way ANOVA with Tukey Multiple 




4.4.2 A Comparison of the Cytotoxic Effects of Fatty Acid on Single Compounds: 
Gentiopicroside, Sweroside, and Silymarin Pre-treated THLE-2 cells (THLE-2) 
 
In a similar fashion to HepG2 cells, THLE-2 cells treated with phytochemicals: 
gentiopicroside, sweroside and swertiamarin showed reduced AA cytotoxic effects in 
terms of diminished cell viability compared to control cells which had not been primed 
with phytochemicals. Using THLE-2 cells helped to determine if cell growth 
enhancement was only limited to HepG2 cells or could be seen in other cell types such 
as THLE-2 cells which are hepatocytes transformed with SV40 large T antigen. Cell 
viability was within the range of 77 to 153 % for gentiopicroside which elicited the 



































































control. There was a general trend of cell viability reducing with increase in AA 
concentration.  Cells which were devoid of priming with phytochemicals but exposed 
to AA (10-80 μM) yielded viabilities of 35-76 %. Other phytochemicals including 
sweroside, swertiamarin and silymarin enhance cellular viability as well by up to 137 
%.  The treatment of hepatocytes with phytochemicals alone did not appear to diminish 
cell viability of hepatocytes but rather enhanced it with viabilities of 127, 134, 140, 
153 % recorded for swertiamarin, sweroside, silymarin and gentiopicroside 
respectively as shown in Fig 4.4. 
 
 
Fig. 4.4 Hepatocyte protection conferred on THLE-2 cells by phytochemical pre-treatment for 24 h. 
For all phytochemical pre-treated hepatocytes, AA cytotoxicity decreased compared with untreated 
cells. GM-treated hepatocytes presented the highest viabilities (77-151%) in the presence of AA (10-80 
μM). Hepatocytes treated with only phytochemicals (i.e. vehicle control) yielded viabilities up to 153 
%. The four phytochemicals Data presented as mean±SD Two-way ANOVA with Tukey Multiple 
































































4.4.3 A Comparative Assessment of Hepatoprotective Effects of Pre-Treatment with 
Gentiana lutea and Gentiana macrophylla compared to Single Compounds: 
Gentiopicroside and Silymarin against Cytotoxic Effects of Arachidonic Acid 
Prior to completing MTT assays, a comparative MTT assay was performed to compare 
the two leading Gentiana species (macrophylla and lutea) as per MTT assay results in 
chapter 3 with the top two performing single compounds (gentiopicroside and 
silymarin) based on MTT assay results from section 4.3.1. This was aimed at forming 
a basis for potentiation studies and also to investigate in part, the possible synergistic 
effects which could be obtained by combining the dominant single compounds in the 
plant extracts. Furthermore, this comparison was also aimed at forging a foundation 
for studies comparing the possible use of the whole root extract in a future wellness 
hepatoprotective agent against using the single compounds individually as 
hepatoprotectives. The results of these comparisons were preliminary and further in-
vivo studies and full scale clinical trials would need to be conducted in order to 
properly establish the usage of these extracts as a wellness product and also draw a 
conclusive comparison between the phytochemicals and the Gentiana species extracts 
studied. The results showed that gentiopicroside pre-treated hepatocytes had the 
highest viability of up to 124% when treated with (10 to 30 µM AA), however, at 80 
µM AA, lutea and macrophylla pre-treated hepatocytes had a higher viability (78% 
and 72%) than silymarin treated hepatocytes (70%) and also at par with 
gentiopicroside at the 80 µM AA treatment with gentiopicroside pre-treated cells 
viable at 80.2% (Fig 4.5). These results suggest possible influence of synergistic effect 
by different phytochemicals since the levels of gentiopicroside present in the 10 
µg/mL lutea and macrophylla refluxed extracts (i.e. 1µg/mL (2.8 µM) and 0.4µg/mL 
(1.2 µM)) as per HPLC analysis were lower than the 20 µM found in the single 
compound. These scenarios were further analysed in more details in the discussion.    
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Fig 4.5 Comparative Assessment of Hepatoprotective Effects of Pre-Treatment with 
Gentiana lutea and Gentiana macrophylla compared to Single Compounds. Graph shows 
highest viability in gentiopicroside treated hepatocytes over 150% in the presence of fatty 
acids. Two-way ANOVA with Comparison of phytochemical/extract treatment factor and 
control (***p=0.0002) and (****p<0.0001). 
 
4.4.4 A Comparison of the Effects of G. lutea, G. macrophylla and Single 
Compounds: Gentiopicroside, Sweroside, and Silymarin pre-treatment on 
Hepatocyte Mitochondrial Function in the Presence of Arachidonic Acid  
The seahorse mitochondrial stress test enabled the measurement of basal respiration, 
ATP production, proton leak, maximal respiration, spare respiratory capacity and non-
mitochondrial respiration in hepatocytes pre-treated with Gentiana lutea (0.01 
mg/mL), Gentiana macrophylla (0.01 mg/mL), gentiopicroside, sweroside and 
silymarin (20 μM) before being exposed to arachidonic acid (30 μM). By injecting 
oligomycin, FCCP, antimycin and rotenone, the various complexes were inhibited as 
shown in (Fig 4.2) and explained in section 4.2.4 to enable the measurement of basal 
respiration, ATP production, spare respiratory capacity, non-mitochondrial 
respiration, maximal respiration and proton leak. A typical seahorse trace for 
gentiopicroside, sweroside and swertiamarin is shown in Fig 4.6. The concentration 
of ATP produced by phytochemical pre-treated hepatocytes appeared to increase 
compared to untreated hepatocytes exposed to arachidonic acid (Fig 4.8.). 
Gentiopicroside pre-treated hepatocytes caused an ATP production of 75 pmol/min 
























































treated hepatocytes compared to untreated hepatocytes exposed to fatty acids (Fig 4.7). 
Sweroside pre-treated hepatocytes presented the highest basal respiration of 114 
pmol/min followed by gentiopicroside with 109 pmol/min. Pre-treating hepatocytes 
with phytochemicals also enhanced the maximal respiratory capacity of the cells even 
after they were exposed to arachidonic acid (Fig 4.8). This effect was mostly seen with 
sweroside pre-treatment up to 281 pmol/min followed by gentiopicroside up to 192 
pmol/min. Gentiopicroside pre-treated hepatocytes presented the highest non-
mitochondrial respiration of 115 pmol/min followed by sweroside with 80 pmol/min 
(Fig 4.10.). Spare respiratory capacity of hepatocytes was markedly increased by 
sweroside up to 115 pmol/min followed by gentiopicroside up to 95 pmol/min (Fig 
4.11.). As far as proton leak is concerned, it was observed in all the phytochemicals 
used but markedly seen in gentiopicroside and gentiopicroside followed by sweroside 
up to 49 pmol/min (fig 4.12). Considering the effect of whole plant extracts on 
mitochondrial function, ATP production was increased by Gentiana macrophylla and 
Gentiana lutea pre-treatment up 79 pmol/min with the highest increase seen in 
macrophylla species (Fig 4.13b).  Following a similar pattern, basal respiration 
increment was seen upon the application of both extracts with macrophylla species 
enhancing it up to 109 pmol/min which was higher than control cells exposed to fatty 
acids without any Gentiana extract pre-treatment (Fig 4.12a). Maximal respiration, 
spare respiratory capacity, non-mitochondrial respiration and proton leak were all 
increased by lutea and macrophylla treatments with the highest increase seen with 
macrophylla in each case, up to (202, 77,76 and 52 pmol/min) respectively (Fig4.12c-
f). In the case of control cells with DMSO as well as negative control cells with only 
AA treatment reduced OCR rates were recorded for all parameters studied.  
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Fig. 4.6. Typical seahorse mito stress test trace for phytochemicals. Typical seahorse mito stress test 
trace for gentiopicroside, silymarin, swertiamarin and sweroside showing the injection points of 
oligomycin, FCCP, antimycin and rotenone and the resultant effect on oxygen consumption rate (OCR) 
of hepatocytes after injection. 
 
 
Fig. 4.7. Basal respiration graph. Basal respiration from the seahorse mito stress test showing reduced 
basal respiration in control hepatocytes but increased basal respiration up to 114 pmol/min in pre-
treated hepatocytes. Two-way ANOVA with Tukey Multiple Comparison of data shows significance of 
















































































Fig. 4.8. ATP production graph. ATP production calculated from the seahorse mito stress test showing 
reduced ATP production in control hepatocytes but increased ATP production up to 75.9 pmol/min in 
pre-treated hepatocytes. Two-way ANOVA with Tukey Multiple Comparison of data shows significance 
of the effect of treatments with *p<0.05 
 
 
Fig. 4.9. Maximal respiration graph. Maximal respiration calculated from the seahorse mito stress 
test showing maximal respiration in control hepatocytes but increased up to 281 pmol/min in pre-
treated hepatocytes. Two-way ANOVA with Tukey Multiple Comparison of data shows significance of 
































































































































































Fig. 4.10. Non-mitochondrial oxygen consumption graph. Non-mitochondrial oxygen consumption 
calculated from the seahorse mito stress test showing reduced non-mitochondrial Oxygen Consumption 
in control hepatocytes but increased up to114.9 pmol/min in pre-treated hepatocytes. Two-way ANOVA 
with Tukey Multiple Comparison of data shows significance of the effect of treatments with *p<0.05 
 
Fig. 4.11. Spare respiratory capacity graph. Spare respiratory capacity calculated from the seahorse 
mito stress test showing reduced spare respiratory capacity in control hepatocytes but increased up to 
115.2 pmol/min in pre-treated hepatocytes. Two-way ANOVA with Tukey Multiple Comparison of data 
shows significance of the effect of treatments with *p<0.05 
 
 




































































































































































Fig. 4.12. Proton Leak graph. Spare respiratory capacity calculated from the seahorse mito stress test 
showing reduced spare reduced proton leak in control hepatocytes but increased up to 48 pmol/min in 
pre-treated hepatocytes. Two-way ANOVA with Tukey Multiple Comparison of data shows significance 








































































































































































































































































































































































































































































































Fig. 4.13. Seahorse mito stress test of G. lutea and G. macrophylla. Seahorse mito stress test of G. lutea and G. macrophylla showing increased: (a) Basal respiration in pre-
treated hepatocytes up to 108 pmol *p=0.0439;(b)ATP production in pre-treated hepatocytes up to 79.2 pmol **p=0.00284;(c) Maximal respiration in pre-treated hepatocytes 
up to 202.1 pmol *p=0.0212, **p=0.0080;(d) Non-mitochondrial respiration in pre-treated hepatocytes up to 76 pmol *p=0.0132, **p=0.0024;(e)Spare respiratory capacity 





4.4.5 Effect of Gentiana Macrophylla and Single Compounds: Gentiopicroside, 
Sweroside, Swertiamarin and Silymarin pre-treatment on Hepatocyte ROS 
Production in the Presence of Arachidonic Acid 
This test evaluated the ROS scavenging effects of the above-listed phytochemicals in 
comparison to silymarin which is a well-known ROS scavenging phytochemical. In 
this instance, the presence of AA (10 µM) caused an increase in ROS by up to 112% 
which however decreased at higher doses of AA (30, 50 and 80 µM) (Fig 4.13). 
Although there were variations in the amounts of ROS scavenged by the different pre-
treatments, sweroside and silymarin were most consistent and portrayed the best ROS 





























Fig. 4.13. DCF assay results of HepG2 cells exposed to AA. Results of DCF assay showing relative 
fluorescence which depicts the amount of ROS produced at each instant. ROS is scavenged to a degree 
by pre-treatments but markedly in sweroside and silymarin (67 and 71%) respectively. Higher doses of 
AA (30, 50 and 80 µM) shows decrease in the amount of ROS produced. Results analysed by two-way 
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4.4.6 Comparative Assessment of Hepatocyte (HepG2) Protection via Apoptosis and 
Necrosis Prevention by Gentiana Macrophylla and Gentiopicroside  
This study employed the annexin V-FITC-PI assay to assess whether or not pre-
treating hepatocytes with gentiopicroside and Gentiana macrophylla prevented 
apoptosis and necrosis in the presence of 30 µM arachidonic acid. This study was a 
further validation of MTT assays carried out earlier which deduced that Gentiana 
macrophylla pre-treatment enhanced cell viability by up to 118% (section 3.3.5) which 
was the highest among the four Gentiana species tested whereas gentiopicroside 
produced viability up to 159% (section 4.3.3) which was also the highest among all 
the phytochemicals tested. However, the MTT assay was limited in terms of not 
differentiating between apoptotic and necrotic death, hence the need to perform the 
annexin V-FITC-PI assay.  Scatter diagrams of the results showed a high degree of 
apoptosis (75%) and low necrosis (9%) in positive control cells exposed to 1 µg/mL 
actinomycin (Fig 4.14 (a) and Fig 4.15). Negative control cells seeded with DMEM 
and DMSO 0.1 % only, also showed a high proportion of live cells (97%) (Fig 4.14(b) 
and Fig 4.15). Treatment of hepatocytes with 30 µM AA increased apoptosis up to 
56% as seen in Fig 4.14 (c) and Fig 4.15. Pre-treatment of hepatocytes with 
gentiopicroside and Gentiana macrophylla prior to arachidonic acid exposure 
increased the proportion of live cells up to 87 and 95 % respectively while reducing 
apoptosis to 10 and 3% Fig 4.14 (d-e) and Fig 4.15. Necrosis was also reduced 
significantly in the presence of both pre-treatments.  
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Fig. 4.14. Results of Annexin V-FITC and PI assay. (a) Scatter diagrams of positive control cells 
exposed to 1µg/mL actinomycin showing a high level of apoptosis (b) Negative control cells seeded 
with DMEM and 0.1%DMSO only showing a high proportion of live cells. (c) Cells with 30 μM AA 
only and no drug pre-treatment presenting live, apoptotic and necrotic cells. (d) Cells with 20 μM GP 
pre-treatment for 24 h before 30 μM AA exposure. (e) Cells with 10 µg/mL GM pre-treatment for 24 h 
before 30 µM AA exposure and (f) flow cytometry gating strategy 
 
Fig. 4.15. Histogram showing level of apoptosis and necrosis in hepatocytes pre-treated with GP and 
GM. Apoptosis is reduced by up to 53.3% in GM pre-treated hepatocytes compared to control cells 
without any pre-treatment prior to AA exposure. Two-way ANOVA with Tukey Multiple Comparison of 
data shows statistically significant difference between GM/GP pre-treated cells and control cells 
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After discovering gentiopicroside, sweroside and swertiamrine in all four Gentiana 
species, and determining that the extracts conferred a degree of hepatocyte protection, 
this study aimed to establish whether or not the phytochemicals found in the extracts 
conferred any form of hepatocyte protection via the pre-treatment method which 
proved most effective in assessing the hepatocyte protection provided by Gentiana 
species as seen in section 3.3.5 following an MTT assay. It was generally observed 
that phytochemicals: gentiopicroside, sweroside and swertiamarin conferred 
hepatocyte protection in terms of enhancing cell growth by promoting mitochondrial 
function in the presence of AA, preventing apoptosis and the build-up of ROS. These 
effects were in some cases greater than those elicited by silymarin.  
In this study, gentiopicroside pre-treated hepatocytes emerged with the highest 
viability, followed by silymarin and then finally sweroside in order of decreasing cell 
viability in both HepG2 cells and THLE-2 cells. This result agreed with studies by 
(Zhao et al., 2015) showing that after pre-treating chondrocytes with 50-150 µg/mL 
of gentiopicroside for 24 h followed by MTT, there was no toxic effects present but 
rather increased function. A mitogenic attribute of gentiopicroside was also observed 
with increased cell replication. This attribute needs to be further investigated to gain 
more understanding. Gentiopicroside is known to possess hepatoprotective effects on 
d-galactosamine and lipopolysaccharide induced hepatic failure (Lian, 2010). 
Furthermore, gentiopicroside was shown to exhibit hepatoprotective effects on IL-1β 
induced inflammation response in rat articular chondrocyte. Silymarin and 
glycyrrhizin have been shown to use a common hepatoprotective pathway in 
protecting the liver from primary biliary cirrhosis in tests using HepG2 cells (Karim, 
2014). Furthermore silymarin has been found to be an effective hepatoprotective agent 
against fatty liver disease induced in rats (Zhang et al., 2013). Bearing these in mind 
the phytochemicals were tested alongside silymarin in order to obtain a known and 
familiar point of reference. Sweroside, which was the third most effective 
phytochemical in terms of cell viability maintenance in this study has shown 
hepatoprotective properties against carbon-tetrachloride induced injury in rats 
(Mihailovic et al., 2013). It was however observed that cell viability enhancement was 
more pronounced in HepG2 cells than THLE-2 cells. This could be because, HepG2 
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cells possess higher sensitivity for basic compounds whereas THLE-2 cells possessed 
higher sensitivity for acidic and neutral compounds (Shah et al., 2014).  
In studies comparing Gentiana lutea and Gentiana macrophylla to gentiopicroside via 
MTT it was observed that at 80 µM AA, lutea and macrophylla pre-treated hepatocytes 
had a higher viability (78% and 72%) than silymarin treated hepatocytes (70%) and 
also at par with gentiopicroside at the 80 µM AA treatment with gentiopicroside pre-
treated cells viable at 80.2%. At 10 and 30 µM AA gentiopicroside produced the 
highest viabilities in both cases over 50 % above control showing a mitogenic effect.  
These results suggest possible influence of synergistic effect by different 
phytochemicals in the extracts especially when faced with higher concentrations of 
AA (80 30 µM AA) since the levels of gentiopicroside present in the 10 µg/mL 
refluxed extracts of Gentiana lutea and Gentiana macrophylla (i.e. 1 µg/mL (2.8 µM) 
and 0.4µg/mL (1.2 µM)) respectively as per HPLC analysis were lower than the 20 
µM found in the single compound. The MTT assay results observed showed that pre-
treated hepatocytes had substantial amounts of mitochondrial dehydrogenases which 
converted the MTT’s yellow tetrazone to purple coloured formazan. 
 The next step entailed further studying mitochondrial function in terms of ATP 
production, basal respiration, maximal respiration, spare respiratory capacity, proton 
leak and non-mitochondrial respiration in pre-treated (i.e. primed) hepatocytes via the 
seahorse mitochondrial stress test. This was to determine if any of these parameters 
had any bearing on maintenance of cell viability by the named phytochemicals. The 
initial injection of 5 µM oligomycin suppressed complex V and ATP synthase, 
enabling the measurement of ATP production, after subtracting from basal oxygen 
consumption rate. Impaired mitochondrial respiration and hepatic ATP synthesis has 
been associated with the accumulation of fatty acids in hepatocytes (Paradies et al., 
2014). However, phytochemical pre-treated hepatocytes in this study had a higher rate 
of ATP production of up to 75 pmol/min observed with gentiopicroside compared to 
untreated hepatocytes which were exposed to 30 µM of arachidonic acid. Although, 
the rate of ATP production was increased across all pre-treated hepatocytes, a slightly 
higher increase was seen in G. macrophylla pre-treated hepatocytes compared to the 
single phytochemicals. Phytochemicals such as gentiopicroside, sweroside and 
amarogentin which are gastro-protective and hepatoprotective have been found in G. 
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lutea and G. macrophylla extracts (Singh, 2008). Bearing this in mind, there is a 
possibility of synergistic effect being demonstrated by a combination of the 
phytochemicals present in G. macrophylla responsible for the increased ATP 
production levels compared to the individual single compounds. This possibility 
requires further investigation in potentiation experiments aimed at determining 
whether or not combination of phytochemicals from Gentiana species can better 
enhance hepatoprotective action.  
Mitochondrial respiration is essential due to the electrochemical gradient it generates 
which is utilised in the production of ATP (Paradies et al., 2014). The injection of 
antimycin A and rotenone suppressed complexes I & III respectively which enabled 
the measurement of non-mitochondrial respiration deducted from basal oxygen 
consumption rate to determine basal respiration. In this instance, the amount of 
mitochondrial respiration was decreased in hepatocytes which lacked 
phytochemical/extract pre-treatment compared to pre-treated hepatocytes up to 115 
pmol/min for gentiopicroside. Following a similar pattern basal respiration, maximal 
respiration and spare respiratory capacity were all increased in phytochemical/extract 
pre-treated as described in the results at section 4.4.4. These results denote the 
possibility that phytochemicals: gentiopicroside, sweroside and swertiamarin may 
protect hepatocytes form arachidonic acid induced cytotoxicity by enhancing 
mitochondrial function in terms of ATP production, basal respiration of cells, 
increasing cellular respiratory capacity as seen in maximal respiration results and also 
broadening the spare respiratory capacity of hepatocytes which is required to meet 
rapid energy demands of the cells especially for dealing with a high influx of fatty 
acids (AA) as seen in Fig 4.6 to 4.12. However, gentiopicroside displayed mitogenic 
effects. 
Gentiopicroside pre-treated cells had a very high non-mitochondrial respiration 
capacity of 115 pmol/min raising the possibility that the effects of gentiopicroside on 
hepatocytes extend beyond the mitochondria into other cellular organelles. This 
however needs to be confirmed through further investigations. There is evidence 
which indicates that hepatic mitochondrial dysfunction is crucial to the pathogenesis 
of NAFLD. This is because the resultant electron flow disruption associated with a 
dysfunctional mitochondrial respiration causes the preceding respiratory intermediates 
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to transfer electrons to molecular oxygen, hence producing  superoxide anions and 
hydrogen peroxide in the process (Wei et al., 2008). Hence the protection and 
enhanced function conferred by gentiopicroside, sweroside, swertiamarin and 
Gentiana extracts to the mitochondria could be a point of intervention in the 
pathogenesis of NAFLD.  
Proton leak is one key factor which affects mitochondrial coupling efficiency and ROS 
production. It is cell-type specific, caused by mitochondrial anion carriers directly 
proportional to cellular metabolic rate (Jastroch et al., 2010). This correlation between 
proton leak and cellular metabolic rate may have contributed to the increased amount 
of proton leak observed in pre-treated HepG2 as seen in Fig 4.12 and 4.13(f). The 
phytochemicals gentiopicroside and sweroside which produced the highest ATP 
productions also observed increased proton as also seen in the instance of Gentiana 
macrophylla. The site for proton leak is in the inner mitochondrial membrane of 
eukaryotes and accounts for about 20 % of standard metabolic rates in rats (Stuart et 
al., 1999). As a result, lower levels of proton leak of up to 21 pmol/min was observed 
for control cells even though they had no phytochemical or plant extract pre-treatment.  
Linked to the mitochondria is ROS production, since the mitochondria serves as a 
major intracellular source of ROS generated at complex I and III (complex I and III 
was assessed in section 4.3.4 via seahorse mito stress assay using antimycin and 
rotenone) of the respiratory chain. Increase in the amount of ROS has been linked to 
DNA mutations, ageing, apoptosis and necrosis (Orrenius, 2007). ROS has been 
successfully measured in HepG2 cells using a fluorescent probe 2,7-
dichlotofluorescein diacetate (DCFH-DA) (Sohn et al., 2005). The DCF-DA ROS 
assay performed in this study showed that the phytochemicals (sweroside, silymarin 
and swertiamarin) scavenged ROS produced. Secoiridoid glycosides inhibit free 
radical activity and prevent the onset of peroxidation reactions (Gülçin et al., 2009). 
However, sweroside possessed the highest ROS scavenging effect, followed by 
silymarin and swertiamarin as shown in section 4.3.5. Sweroside has been found to 
possess reactive oxygen species scavenging effects (Nawa et al., 2007). In HepG2 
cells, silymarin showed antioxidant and hepatoprotective activity against tacrine-
induced cytotoxicity (Jung et al., 2004).  A dose of 10-100 µM silymarin possessed 
antioxidant effects in HepG2 cells against bleomycin which is a known ROS generator 
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(Angeli et al., 2009). It was observed that upon treating hepatocytes with 10 µM 
arachidonic acid, ROS levels were increased up to 112%. This was to be expected 
because studies by (Cocco et al., 1999) indicate that arachidonic acid causes an 
increase in the production of ROS when it interacts with mitochondrial electron 
transport chain by causing an increased production of hydrogen peroxide in addition 
to the mitochondria respiring with pyruvate, malate or succinate as substrate. This 
increase in ROS production was reduced at a dose of 80 µM AA in, possibly as a result 
of increased cell death in untreated hepatocytes due to high oxidative stress. Oxidative 
stress leading to cell death can be caused by an imbalance between reactive oxygen 
species and antioxidant defenses(Klamt et al., 2002). Hence the lack of an active ROS 
scavenger can be detrimental to viability of hepatocytes exposed to ROS producing 
compounds.  
ROS levels in gentiopicroside pre-treated hepatocytes were quite high, although not 
as high as control cells treated with only 10 µM AA and not primed with 
gentiopicroside or other phytochemicals tested. Enhanced mitochondrial function 
produced higher amount of ROS via the mitochondrial electron transport chain than 
ROS produced by glutathione depletion (Tan et al., 1998b). Hence enhancing 
mitochondrial function without a concurrent increase in maximal respiratory capacity 
could lead to the production high amounts of ROS above cellular respiratory capacity. 
As seen in the seahorse mito stress assay, gentiopicroside and sweroside acted on 
mitochondrial complex I and III producing a very high basal respiration but sweroside 
pre-treated cells, apart from having a high basal respiration had the highest maximal 
respiration capacity whereas gentiopicroside pre-treated cells had a low maximal 
respiration capacity. This may account for the better performance of sweroside than 
gentiopicroside in managing ROS generated by hepatocytes. Under normal conditions, 
a percentage of oxygen consumed by the mitochondria of hepatocytes are changed 
into superoxides by complex I and III (Ligeret et al., 2008). Mitochondrial electron 
transport chain induced superoxide production is also linked to increased protein 
oxidation (Klamt et al., 2002) . This factor also explains the production of ROS by 
control hepatocytes which had neither been pre-treated nor exposed to arachidonic 
acid, since the mitochondria has an inherent ability to produce a level of ROS.   
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Loss of cell function and eventual apoptosis or necrosis are the end results of oxidative 
stress emanating from high ROS levels (Halliwell and Gutteridge, 2015). The annexin 
V-FITC-PI assay assessed the anti-apoptotic/anti-necrotic effect of gentiopicroside 
and Gentiana macrophylla pre-treatment against arachidonic acid induced 
apoptosis/necrosis. The presence of polyunsaturated fatty acids such as arachidonic 
acid coupled with the increased production of reactive oxygen intermediates by cells 
expressing CYP2E1 in HepG2 cells causes cellular toxicity leading to lipid 
peroxidation and eventually apoptosis (Chen et al., 1998). Arachidonic acid is also an 
intermediate in apoptosis signalling regulated by cytochrome c oxidase subunit 2 
(COX-2) and  fatty acid-CoA ligase 4 (FACL4) (Cao et al., 2000). These support the 
increased necrosis and apoptosis seen in control cells exposed to arachidonic acid 30 
µM without any Gentiana macrophylla or gentiopicroside pre-treatment seen in 
section 4.4.6. (Fig 4.14c). Apoptosis was however markedly reduced in 
gentiopicroside and Gentiana macrophylla pre-treated cells by up to 53.3%. The 
antiapoptotic effect of gentiopicroside is credited with its hepatoprotective effects 
against D-galactosamine/lipopolysaccharide-induced hepatic failure (Lian, 2010). 
Mitochondrial dysfunction causes the release of cytochrome c and other pro-apoptotic 
proteins, which initiates caspase activation and apoptosis. This raises the possibility 
that the anti-apoptotic effect of gentiopicroside may also be linked with its ability to 
improve the efficiency of mitochondrial function in terms of mitochondrial ATP 
production and basal respiration as seen in the seahorse mito stress assay results. It has 
also been reported that Gentiana macrophylla has an apoptosis-inhibition effect 
(Huang et al., 2015). The level of antiapoptotic effect is slightly better for macrophylla 
than gentiopicroside alone, which could be as a result of synergistic effect of sweroside 
and swertiamarin working together with gentiopicroside found in macrophylla. 
Assessing the individual anti-apoptotic effect of sweroside and swertiamarin is a key 
further study area. As stated earlier and independently confirmed, this was the first 
research assessing the mitochondrial function of the four Gentiana species as well as 
their phytochemicals via the seahorse mito stress assay, hence further work in that 





The mitochondria is a key organelle to NAFLD pathogenesis in terms of fatty acid 
oxidation, mitochondrial respiration, ATP production as well as fatty acid synthesis. 
These studies have shown that pre-treating hepatocytes with G. macrophylla, G. lutea 
and single compounds: gentiopicroside, sweroside and silymarin provides a degree of 
protection which may be attributed to enhancing mitochondrial function in terms of 
ATP production, basal respiration, spare respiratory capacity, maximal respiration, 
proton leak and non-mitochondrial oxygen consumption. This was best was 
gentiopicroside. It has also been observed that apart from enhancing mitochondrial 
function, Gentiana macrophylla and all the above-named phytochemicals most 
notably sweroside, silymarin and swertiamarin protected hepatocytes by scavenging 
ROS produced by arachidonic acid and the mitochondrial electron transport chain. 
Another key mechanism of hepatocyte protection observed was the antiapoptotic 
effect of gentiopicroside and G. macrophylla against arachidonic induced apoptosis 
and necrosis. These investigations have also pointed to the possibility of a synergistic 
action being responsible for elevated hepatocyte protection seen in G. macrophylla. A 
mitotic effect of gentiopicroside as well as Gentiana macrophylla also requires further 
investigation using primary hepatocytes. Further investigation and exploitation in 
potentiation studies are required to determine whether or not hepatocyte protection 
will be enhanced when by combining different active phytochemicals found in 






















This study examined the hypothesis that the methanolic extracts and selected 
phytochemicals (gentiopicroside, sweroside and swertiamarin) of four Gentiana 
species: lutea, macrophylla, rigescens and scabra exhibit hepatoprotective effects in 
non-alcoholic fatty liver disease (NAFLD). In line with the set objectives, the first 
stage of this study entailed an assessment of methanolic extracts of Gentiana species 
via HPLC and HPTLC to identify and quantify the above-listed phytochemicals prior 
to bioactivity screening. The second stage involved an in vitro screening to determine 
the resistance of HepG2 and THLE-2 cells to fatty acid (arachidonic acid) induced 
cytotoxicity in the presence of methanolic extracts of Gentiana species. The third stage 
comprised of investigations into the effects of bioactive Gentiana spp. extracts and 
phytochemicals on mitochondrial function, apoptosis and reduction of oxidative stress 
on HepG2 cells in the presence of fatty acids.  
 
5.2 Stage One – Assessment of Methanolic Extracts of Gentiana Spp.  
This step served as a validation step for the four Gentiana species used throughout this 
study and served as a foundation for understanding the bioactivity of the extracts as 
well phytochemicals identified when used in cell the proceeding cell work. A review 
of literature showed that extraction via refluxing or sonication followed by HPLC or 
HPTLC were the first point of call for the qualitative and quantitative assessment of 
plant extracts prior to in vitro or in vivo screening. In this study however, both HPTLC 
and HPLC assessments of methanolic extracts obtained by both refluxing and 
sonication were performed concurrently to provide a robust verification of all plants 
species used and to aid in deciphering the most applicable for this study. Furthermore, 
the use of both gradient and isocratic methods served to provide a comparative 
assessment of the degree of sensitivity of both methods when used to assess the four 
Gentiana species, as well as phytochemicals and also shed more light on different 
outcomes which could be attained based on the method employed.  
 
Higher amounts of phytochemicals were obtained from refluxed plants compared to 
sonicated ones. A broader spectrum of peaks were observed for gradient HPLC runs 
than the isocratic mode. These observations will be useful guide for studying these 
four Gentiana species in making an informed choice of methodology for qualitative 
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and quantitative assessment. This stage fulfilled the desired objective with the 
authentication of the four Gentiana species: lutea, macrophylla, scabra and rigescens 
and, the identification and quantitation of phytochemicals: gentiopicroside, sweroside 
and swertiamarin of which gentiopicroside was most abundant in all species. 
Methanolic extracts of Gentiana lutea presented the highest amount of each 
phytochemical quantitated. Having achieved this objective, the next step was to screen 
methanolic extracts (refluxed) of the four Gentiana species for their bioactivity on 
hepatocytes (HepG2, VA-13 and THLE-2) in the presence of fatty acid (arachidonic 
acid).    
 
5.3 Stage Two – Iv Vitro Screening of Methanolic Extracts of Gentiana Spp  
This stage was initialised by assessing the survival rate of hepatocytes (in terms of cell 
viability) under each plant species as well as the best mode of application (i.e. pre-
treatment, co-administration or post-treatment) and time of exposure. This was done 
through trypan blue, MTT and LDH assays. At this stage, the focus was not yet on 
individual phytochemicals but to determine the best Gentiana species extract in terms 
of resisting the cytotoxicity of arachidonic acid. Arachidonic acid exhibited greater 
cytotoxicity in HepG2 cells in comparison with other fatty acids such as palmitic, 
hence the choice of arachidonic acid. This was further confirmed by assessing the 
cytotoxicity of arachidonic acid on hepatocytes in MTT, LDH and trypan blue assays.  
The extent of cell viability maintained in hepatocytes treated with Gentiana plant 
extracts in the presence of fatty acids was the preliminary indication of hepatocyte 
protective effect. Checking cell viability of hepatocytes in different treatment 
timelines as well as treatment modes also aimed at portraying the most effective 
application of Gentiana plant extracts to obtain hepatocyte protection. This was found 
to be pre-treatment (priming) of hepatocytes with Gentiana extracts for 24 h prior to 
arachidonic acid exposure. Gentiana macrophylla was found to be the most effective 
species in conferring hepatocyte protection but showed a mitogenic effect. This was 
followed by Gentiana lutea, Gentiana scabra and Gentiana rigescens in decreasing 
order of hepatocyte protection. A similar pattern was seen in THLE-2 cells pre-treated 
with the above-named extracts in the presence of arachidonic acid. Attaining this 
objective raised further questions concerning the role played by the phytochemicals 
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identified in stage one in providing the hepatocyte protection seen in Gentiana extracts 
and also the most effective phytochemical (s). Furthermore, it was essential to further 
investigate the enhanced cell growth seen in stage two to determine the extent to which 
necrosis and apoptosis were prevented by Gentiana extracts and phytochemicals. 
These studies were conducted in the third stage of this study. 
 
5.4 Stage Three – Effects of Bioactive Gentiana species extracts and 
Phytochemicals on Mitochondrial Function, Apoptosis and Reduction of 
Oxidative stress  
In order to determine the means by which Gentiana species extracts and identified 
phytochemicals protected hepatocytes, their effects on mitochondrial function in terms 
of ATP production, basal respiration, maximal respiration, spare respiratory capacity, 
proton leak and non-mitochondrial oxygen consumption in the presence of arachidonic 
acid was performed in the first study of its kind for Gentiana spp. extracts and 
phytochemicals. Further insight into the mode of hepatocyte protection was obtained 
in flow cytometric annexin V-FITC and DCF ROS assays.  
 
Assaying the three phytochemicals: gentiopicroside, sweroside and swertiamarin in 
comparison with positive control silymarin provided further understanding of the 
means by which hepatocyte protection was achieved by the Gentiana extracts. The 
identified phytochemicals enhanced cell viability of in varying degrees with 
gentiopicroside and Gentiana macrophylla showing the highest potency in this regard 
for both HepG2 and THLE-2 cells. Both Gentiana macrophylla and gentiopicroside 
were further analysed via annexin-V FITC to gain further understanding of cell 
viability promoted by them in terms of the prevention of necrosis and apoptosis. 
Although both enhanced cell viability, the 10 µg/mL Gentiana macrophylla 
(containing 0.4 µg/mL (i.e. 1.2 µM) gentiopicroside as determined by HPLC analysis 
portrayed higher anti-apoptotic activity than 20 µM gentiopicroside. This points to 
possible synergistic effects of other phytochemicals including (0.24 µM sweroside and 
0.30 µM swertiamarin) found in 10 µg/mL Gentiana macrophylla working in 
combination with the 1.2 µM gentiopicroside to present a more enhanced anti-
apoptotic effect in the hepatocytes. This observation has set a foundation for further 
work which could involve a combination of gentiopicroside, sweroside and 
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swertiamarin in varying proportions for testing on hepatocytes to determine their 
hepatocyte protection effect. Furthermore, gentiopicroside eliciting a synergistic effect 
at a dose as low as 1.2 µM opens up the possibility of it being combined with other 
mainstream hepatoprotective agents such as reducdyn (n-acetyl-d, l-homocysteine 
thiolactone) to enhance their effect as well as possibly reducing their side-effects. This 
assumption would however require further studies to validate it. 
 
High fat diet, coupled with decreased ATP production, decreased mitochondrial 
respiration as well as reduced fatty acid oxidation constitutes the first hit phase leading 
to NAFLD proceeded by the second hit leading to NASH. It is expected that an 
effective hepatocyte protective agent would intervene at the first hit stage to prevent 
the onset of NAFLD. Based on results from this study, it can be deduced that Gentiana 
phytochemicals protect hepatocytes from the first hit in NAFLD by increasing ATP 
production (most markedly noticed with gentiopicroside pre-treatment), 
mitochondrial basal respiration, maximal respiration, spare respiratory capacity as 
well as non-mitochondrial oxygen consumption as summed up in Table 5.1. Hence, 
the hepatocyte’s capacity to metabolise a high influx of fatty acids is increased by the 
phytochemicals, alongside an increased output capacity in ATP production (which 
implies increase beta oxidation) while scavenging ROS produced as a result of this 
increased rate of metabolism to prevent them from harming the liver cells. 
Furthermore, the Gentiana phytochemicals maintain the longevity of the hepatocytes 
by preventing necrosis and apoptosis in the presence of fatty acids. By instituting these 
counter-measures, hepatocyte protection is achieved and some of the effects of the 
first hit leading to NAFLD are minimised or prevented. Gentiopicroside and sweroside 
performed better than silymarin in most of the parameters tested in this study which 
presents both of them as leading candidates for combined usage as hepatocyte 
protectors when compared to swertiamarin and silymarin.  
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Table 5.1 Summary table of mode and intensity of hepatocyte protection 
 Gentiana  
macrophylla 






Cell viability +++++ +++++# +++ ++++ ++ ++++ +++ ++ 
ATP production +++++ +++++ ++++ +++ +++ ++++ N/A N/A 
Basal respiration +++++ ++++ +++++ +++ +++ ++++ N/A N/A 
Maximal respiration +++++ ++++ +++++ +++ ++ ++++ N/A N/A 
Non-mitochondrial 
oxygen consumption 
+++++ +++++ ++++ +++ +++ ++++ N/A N/A 
Spare respiratory capacity +++++ ++++ +++++ +++ ++ ++++ N/A N/A 
ROS scavenging +++ ++ +++++ ++++ +++ N/A N/A N/A 
Anti-apoptosis +++++ ++++ N/A N/A N/A N/A N/A N/A 
 
+++++ Showed excellent performance when compared with control 
++++   Showed second best performance compared to control 
+++     Showed third best performance compared to control 
++       Showed fourth best performance compared to control 
#          showed mitogenic effect 
N/A     Not applicable
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The summary points are as follows: 
 A mitogenic attribute markedly observed in gentiopicroside and Gentiana 
macrophylla should be further investigated using primary hepatocytes without any 
modifications. This would help to deepen the understanding of mitogenic effect 
being observed and provide further ways of addressing it. 
 Cell growth may be promoted by Gentiana species phytochemicals which work in 
a synergistic manner to enhance mitochondrial function, scavenge ROS and 
prevent apoptosis hence maintaining cell longevity. Based on the results a 
promising synergistic combination which can be further investigated incudes a 
gentiopicroside: sweroside combination. Such a combination will bring together 
increased ATP production by gentiopicroside coupled with an increased maximal 
respiratory capacity enabling the hepatocyte to cope with the increased respiratory 
rate. Sweroside will also aid the scavenging of increased ROS which is associated 
with enhanced mitochondrial function whereas gentiopicroside will maintain cell 
survival rate by preventing apoptosis and promoting cell viability.    
 Gentiana macrophylla which was the best performing specie as well as 
gentiopicroside both prevented necrosis and apoptosis as seen the annexin V-FITC 
PI assay. Even though the main focus was on the best performing Gentiana species 
and phytochemicals for annexin-V FITC, further work could be done by testing 
each of the remaining Gentiana species as well as other species of Gentiana not 
covered in this study.  
  Cell viability is preserved by the scavenging of ROS particularly by sweroside 
followed by swertiamarin and gentiopicroside. 
 Gentiana species extracts G. lutea and G. macrophylla as well as phytochemicals: 
gentiopicroside, sweroside and swertiamarin enhanced mitochondrial function in 
terms of increased maximal respiratory capacity most notably with sweroside, as 
well as increased spare respiratory capacity enabling the cell to respond to high 
energy demands. 
 G. lutea and G. macrophylla as well as phytochemicals: gentiopicroside, 
sweroside and swertiamarin promoted ATP production with the highest ATP 
production seen in gentiopicroside treatment. 
 G. lutea and G. macrophylla as well as phytochemicals: gentiopicroside, 
sweroside and swertiamarin increased the basal respiration in hepatocytes, hence 
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improving the efficiency with which they respire and consume oxygen while in a 
resting state. Furthermore, non-mitochondrial oxygen consumption was increased 
pointing to the possibility that other hepatocellular organelles were functionally 
enhanced by the phytochemicals. This needs to be further researched to obtain the 




5.5 Further Work 
 
Fig 5.1 Metabolic pathways of a high fat diet leading to NAFLD. This diagram depicts the metabolic 
pathways of a high fat diet and the sections of this thesis investigating possible points of intervention 
by Gentiana spp and phytochemicals in the fat metabolism pathway and potential points for further 
study. (Gyamfi, et al, 2009)(Song et al., 2007).  
 
This study has portrayed that the four Gentiana species: lutea, macrophylla, 
scabra and rigescens possess hepatocyte protection effects derived from their 
phytochemicals some of which are: gentiopicroside, sweroside and swertiamarin. 
Further work could be done on other phytochemicals found in Gentiana plants 
such as loganic acid and amarogentin to determine their hepatocyte protective 
effects in terms of mitochondrial function (seahorse mito stress test). As circled 
in (Fig 5.1), the role played by Gentiana species and phytochemicals 
(gentiopicroside, sweroside and swertiamarin) in preventing inflammation can 
also be assessed in a further study. In-vitro and in-vivo models can also be used 
to further investigate if the four Gentiana species and phytochemicals play any 
role in stabilizing liver enzymes AST and ALT which are elevated in inflamed 
liver tissue. Another scenario for further study is the role of Gentiana species and 
phytochemicals in preventing lipid accumulation in hepatocytes. This study has 
set a foundation for the assessment of hepatocyte protection derived from 
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Gentiana plants especially in terms of mitochondrial and non-mitochondrial 
respiration. It will not only deepen our understanding of hepatocyte protection but 
stimulate novel ideas in the screening of phytochemicals and further research in 








Appendix A: Intra-day Gentiopicroside Calibration Tables 
  
 
GPS (0.5 µg/mL)  
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
1 12.413 0.0722 0.60 
2 12.414 0.0723 0.59 
3 12.413 0.0722 0.60 
AV 12.4135 0.072233333 0.60 
SD 0.000707107 7.07107E-05 0.001414214 






  GPS (1 µg/mL)  
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
1 12.413 0.1424 1.21 
2 12.413 0.1444 1.22 
3 12.412 0.1444 1.21 
AV 12.413 0.143733333 1.215 
SD 0 0.001414214 0.007071068 





GPS (5 µg/mL)  
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
1 12.413 0.7572 6.02 
2 12.413 0.7544 6.01 
3 12.413 0.7580 6.02 
AV 12.413 0.756533333 6.015 
SD 0 0.001890326 0.007071068 
RSD 0 0.249866882 0.117557237 
  GPS (10 µg/mL)  
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
 1 12.413 1.4413 11.89 
 2 12.417 1.4457 11.97 
 3 12.413 1.4433 11.93 
AV 12.415 1.443433333 11.93 
SD 0.002828427 0.002203028 0.056568542 


















GPS (20 µg/mL)  
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
  12.42 2.7029 23.05 
  12.423 2.7041 23.00 
  12.423 2.7037 23.10 
AV 12.4215 2.703566667 23.025 
SD 0.00212132 0.00061101 0.035355339 
RSD 0.017077811 0.022600149 0.153551961 
  GPS (15 µg/mL)  
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
  12.413 2.3261 19.52 
  12.413 2.3193 19.60 
  12.413 2.3245 19.75 
AV 12.413 2.3233 19.56 
SD 0 0.004808326 0.056568542 





GPS (50 µg/mL)  
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
  12.423 6.8915 58.20 
  12.427 6.8816 58.25 
  12.423 6.9010 58.30 
AV 12.425 6.891366667 58.23 
SD 0.002828427 0.009700687 0.035355339 
RSD 0.022764001 0.140765798 0.060721922 
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Appendix B: Intra-day Sweroside Calibration Tables 
  SWE (0.5µg/ml)   
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
1 12.94 0.1563 1.34 
2 12.92 0.1565 1.35 
3 12.94 0.1565 1.34 
AV 12.93 0.156433333 1.345 
SD 0.014142136 0.00011547 0.007071068 









SWE (15µg/ml)  
  GPS (1µg/ml)   
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
1 12.94 0.3131 2.68 
2 12.94 0.313 2.68 
3 12.94 0.313 2.67 
AV 12.94 0.313033333 2.68 
SD 0 5.7735E-05 0 
RSD (%) 0 0.018443731 0 
  SWE (5µg/ml)   
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
1 12.947 1.5653 13.39 
2 12.95 1.5645 13.40 
3 12.95 1.5664 13.46 
AV 12.9485 1.5654 13.395 
SD 0.00212132 0.000953939 0.007071068 
RSD (%) 0.01638275 0.060939006 0.05278886 
    
  SWE (10µg/ml)  
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
  12.94 3.0422 25.76 
  12.94 3.0302 25.7 
  12.94 3.0363 25.71 
AV 12.94 3.036233333 25.73 
SD 0 0.006000278 0.042426407 
RSD (%) 0 0.197622419 0.164890816 
 131 
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
  12.94 4.69 32.34 
  12.94 4.7 32.38 
  12.94 4.69 32.3 
AV 12.94 4.693333333 32.36 
SD 0 0.005773503 0.028284271 







SWE (50µg/ml)   
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
  12.95 15.2453 132.48 
  12.953 15.2474 132.50 
  12.947 15.233 132.48 
AV 12.9515 15.2419 132.49 
SD 0.00212132 0.007778817 0.014142136 





SWE (20µg/ml)  
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
  12.937 5.9993 42.07 
  12.937 5.982 42.04 
  12.94 5.9892 42.05 
AV 12.937 5.990166667 42.055 
SD 0 0.008690416 0.021213203 
RSD (%) 0 0.145078036 0.050441573 
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Appendix C: Intra-day Swertiamarin Calibration Tables 
  SWT (0.5µg/ml)   
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
1 11.717 0.15145 1.61 
2 11.715 0.15143 1.63 
3 11.717 0.1514 1.60 
AV 11.716 0.151426667 1.62 
SD 0.001414214 2.51661E-05 0.014142136 
RSD (%) 0.012070788 0.016619341 0.872971335 
 
 
  SWT (5µg/ml)   
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
1 11.717 1.9791 16.11 
2 11.72 1.9846 16.18 
3 11.717 1.9793 16.11 
AV 11.7185 1.981 16.145 
SD 0.00212132 0.003119295 0.049497475 








  SWT (1µg/ml)   
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
1 11.717 0.303 3.22 
2 11.717 0.3031 3.20 
3 11.72 0.314 3.21 
AV 11.717 0.3067 3.21 
SD 0 0.006322183 0.014142136 
RSD (%) 0 0.019052368 0.440564973 
  
 
SWT (10µg/ml)  
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
 1 11.717 3.1298 24.42 
 2 11.717 3.1282 24.4 
 3 11.713 3.1353 24.43 
AV 11.717 3.1311 24.41 
SD 0 0.003724245 0.014142136 
RSD (%) 0 0.118943658 0.057935828 
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  SWT (15µg/ml)  
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
  11.723 4.9139 40.36 
  11.727 4.915 40.33 
  11.727 4.9262 40.34 
AV 11.725 4.918366667 40.345 
SD 0.002828427 0.006806125 0.021213203 
RSD (%) 0.024123046 0.138381807 0.05257951 
 
 
  SWT (50µg/ml)   
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
  11.727 15.8972 15.32 
  11.73 15.8879 15.35 
  11.723 15.9233 15.3 
AV 11.7285 15.9028 15.335 
SD 0.00212132 0.018352384 0.021213203 








  SWT (20µg/ml)  
  Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
  11.72 6.2427 55.3 
  11.717 6.2258 55.37 
  11.717 6.2272 55.35 
AV 11.7185 6.2319 55.335 
SD 0.00212132 0.009379232 0.049497475 
RSD (%) 0.01810232 0.150503576 0.089450573 
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Appendix D: Intra-day and Inter-Day HPLC Precision of Gentiopicroside, Sweroside and Swertiamarin in Refluxed Gentiana scabra Based 
on Peak Areas with RSD 
 
 Inter-day (n=3) Intra-day 
(n=3) 
(mAU*Min)  


































RSD= 2.95 % 
Swertiamarin 0.07245 
SD=0.007 
RSD = 1.27 % 
0.0768 
SD=0.001 



















Appendix E: Intra-day and Inter-Day HPLC Precision of Gentiopicroside, Sweroside and Swertiamarin in Sonicated Gentiana scabra Based 
on Peak Areas with RSD (in parenthesis) 
 
 
 Inter-day (n=3) Intra-day 
(n=3) 
(mAU*Min)  


































RSD= 0.86 % 
Swertiamarin 0.0130 
SD=0.002 




RSD= 2.99 % 
0.01346 
SD=0.0003 







Appendix F: Intra-day and Inter-Day HPLC Precision of Gentiopicroside, Sweroside and Swertiamarin in Refluxed Gentiana rigescens Based 
on Peak Areas with RSD  
 
 Inter-day (n=3) Intra-day 
(n=3) 
(mAU*Min)  








RSD =1.09 % 
0.2725 
SD=0.005 





















RSD= 1.45 % 
Swertiamarin 0.0085 
SD=0.001 




RSD= 2.97 % 
0.0083 
SD=0.002 
RSD= 1.54 % 
0.0087 
SD=0.005 













Appendix G:  Intra-day and Inter-Day HPLC Precision of Gentiopicroside, Sweroside and Swertiamarin in Sonicated Gentiana rigescens 
Based on Peak Areas with RSD (in parenthesis) 
 
 Inter-day (n=3) Intra-day 
(n=3) 
(mAU*Min)  










RSD =0.12 % 
0.0832 
SD=0.003 





















RSD= 2.49 % 
Swertiamarin 0.0073 
SD=0.001 
RSD = 3.24 % 
0.0080 
SD=0.0003 
RSD= 2.97 % 
0.0083 
SD=0.002 
RSD= 1.54 % 
0.0087 
SD=0.005 












Appendix H: Intra-day HPLC Precision of Gentiopicroside, Sweroside and Swertiamarin in Refluxed 100µg/mL Gentiana lutea Based on 
Peak Areas 
  GPS      SWE   
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU)   Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
R1 12.423 1.0693 9.13  R1 12.95 0.0515 0.4 
R2 12.42 1.0728 9.08  R2 12.95 0.0512 0.4 
R3 12.42 1.0716 9.06  R3 12.95 0.0535 0.4 
AV 12.421 1.071233333 9.09  AV 12.95 0.052066667 0.4 




  SWT  
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
R1 11.727 0.1537 1.14 
R2 11.723 0.1617 1.15 
R3 11.723 0.1615 1.13 
AV 11.72433333 0.158966667 1.14 





Appendix I: Intra-day HPLC Precision of Gentiopicroside, Sweroside and Swertiamarin in Sonicated 100µg/mL Gentiana lutea Based on Peak 
Areas 
 
  GPS      SWE   
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU)   Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
R1 12.42 0.5822 4.83  R1 12.95 0.0264 0.2 
R2 12.42 0.5877 4.84  R2 12.95 0.0275 0.2 
R3 12.42 0.5875 4.85  R3 12.95 0.0271 0.2 
AV 12.42 0.5858 4.84 
 
AV 12.95 0.027 0.2 
SD 0 0.003119295 0.01 SD 2.17558E-15 0.000556776 3.39935E-17 
 
 
  SWT  
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
R1 11.727 0.0765 0.54 
R2 11.723 0.0825 0.55 
R3 11.727 0.0815 0.55 
AV 11.72566667 0.080166667 0.546666667 
SD 0.002309401 0.00321455 0.005773503 








Appendix J: Intra-day HPLC Precision of Gentiopicroside, Sweroside and Swertiamarin in Refluxed 500µg/mL Gentiana macrophylla Based 
on Peak Areas 
 
  GPS      SWE   
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU)   Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
R1 12.417 7.7461 65.21   12.947 0.3466 2.62 
R2 12.417 7.7598 65.33   12.943 0.3461 2.61 
R3 12.417 7.7433 65.16   12.943 0.3461 2.61 
AV 12.417 7.749733333 65.23333333 
 
AV 12.94433333 0.346266667 2.613333333 
SD 0 0.008829685 0.087368949 SD 0.002309401 0.000288675 0.005773503 
 
 
  SWT  
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
 11.72 1.1899 8.22 
 11.72 1.1916 8.19 
 11.723 1.1668 8.16 
AV 11.721 1.182766667 8.19 







Appendix K: Intra-day HPLC Precision of Gentiopicroside, Sweroside and Swertiamarin in Sonicated 500µg/mL Gentiana lutea Based on 
Peak Areas 
 
  GPS      SWE   
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU)   Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
R1 12.42 1.8347 14.89   12.947 0.0824 0.61 
R2 12.423 1.8465 15.06   12.947 0.0855 0.61 
R3 12.42 1.8496 15.12   12.947 0.0816 0.61 
AV 12.421 1.8436 15.02333333 
 
AV 12.947 0.083166667 0.61 
SD 0.001732051 0.007861934 0.119303534 SD 2.17558E-15 0.002059935 0 
 
 
  SWT  
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
 11.727 0.2521 1.68 
 11.727 0.254 1.7 
 11.727 0.2534 1.7 
AV 11.727 0.253166667 1.693333333 









Appendix L:   Intra-day HPLC Precision of Gentiopicroside, Sweroside and Swertiamarin in Refluxed 1000µg/mL Gentiana lutea Based on 
Peak Areas 
 
  GPS      SWE   
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU)   Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
R1 12.417 15.3943 128.83   12.947 0.805 5.46 
R2 12.417 15.4344 128.04   12.943 0.7018 5.48 
R3 12.42 15.4863 128.73   12.947 0.8067 5.49 
AV 12.418 15.43833333 128.5333333 
 
AV 12.94566667 0.771166667 5.476666667 
SD 0.001732051 0.046125951 0.430155011 SD 0.002309401 0.060079309 0.015275252 
         
  SWT  
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
 11.72 2.3619 16.32 
 11.72 2.3622 16.06 
 11.723 2.3767 16.13 
AV 11.721 2.366933333 16.17 







Appendix M: Intra-day HPLC Precision of Gentiopicroside, Sweroside and Swertiamarin in Sonicated 1000µg/mL Gentiana lutea Based on 
Peak Areas 
 
  GPS      SWE   
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU)   Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
R1 12.417 4.4721 36.04   12.943 0.1955 1.42 
R2 12.42 4.472 35.88   12.947 0.1933 1.42 
R3 12.42 4.4816 35.97   12.943 0.2087 1.47 
AV 12.419 4.475233333 35.96333333 
 
AV 12.94433333 0.199166667 1.436666667 
SD 0.001732051 0.005513922 0.080208063 SD 0.002309401 0.008329066 0.028867513 
 
 
  SWT  
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
 11.723 0.618 4.04 
 11.723 0.6165 4.02 
 11.727 0.6186 4.04 
AV 11.72433333 0.6177 4.033333333 









Appendix N:  Intra-day HPLC Precision of Gentiopicroside, Sweroside and Swertiamarin in Refluxed 500µg/mL Gentiana macrophylla Based 
on Peak Areas 
 
  GPS      SWE   
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU)   Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
R1 12.43 2.5764 19.8   12.95 0.2297 1.54 
R2 12.433 2.5849 19.91   12.957 0.2335 1.55 
R3 12.423 2.5788 19.75   12.953 0.232 1.56 
AV 12.42866667 2.580033333 19.82  AV 12.95333333 0.231733333 1.55 
SD 0.005131601 0.004382161 0.081853528  SD 0.003511885 0.001913984 0.01 
 
 
  SWT  
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
 11.687 0.3317 2.14 
 11.687 0.3327 2.15 
 11.683 0.3632 2.19 
AV 11.68566667 0.342533333 2.16 







Appendix O: Intra-day HPLC Precision of Gentiopicroside, Sweroside and Swertiamarin in Sonicated 500µg/mL Gentiana macrophylla Based 
on Peak Areas 
 
  GPS      SWE   
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU)   Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
R1 12.437 0.1677 1.27   12.963 0.0244 0.18 
R2 12.44 0.1675 1.27   12.97 0.0246 0.18 
R3 12.44 0.1658 1.26   12.967 0.0287 0.19 
AV 12.439 0.167 1.266666667  AV 12.96666667 0.0259 0.183333333 
SD 0.001732051 0.001044031 0.005773503  SD 0.003511885 0.002426932 0.005773503 
 
 
  SWT  
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
 11.7 0.0076 0.07 
 11.703 0.0064 0.06 
 11.7 0.0065 0.06 
AV 11.701 0.006833333 0.063333333 









Appendix P: Intra-day HPLC Precision of Gentiopicroside, Sweroside and Swertiamarin in Refluxed 1000µg/mL Gentiana macrophylla Based 
on Peak Areas 
 
  GPS      SWE   
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU)   Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
R1 12.427 5.168 39.57   12.95 0.4617 3.1 
R2 12.423 5.1826 39.72   12.947 0.5026 3.21 
R3 12.423 5.1715 39.65   12.947 0.4684 3.11 
AV 12.42433333 5.174033333 39.64666667  AV 12.948 0.477566667 3.14 
SD 0.002309401 0.007622554 0.075055535  SD 0.001732051 0.021936803 0.060827625 
 
 
  SWT  
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
 11.68 0.6589 4.43 
 11.68 0.6604 4.43 
 11.68 0.7774 4.44 
AV 11.68 0.6989 4.433333333 







Appendix Q:  Intra-day HPLC Precision of Gentiopicroside, Sweroside and Swertiamarin in Sonicated 1000µg/mL Gentiana macrophylla 
Based on Peak Areas 
 
  GPS      SWE   
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU)   Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
R1 12.44 0.3157 2.37   12.97 0.0428 0.34 
R2 12.44 0.3152 2.38   12.967 0.0495 0.36 
R3 12.443 0.3162 2.41   12.967 0.0465 0.34 
AV 12.441 0.3157 2.386666667  AV 12.968 0.046266667 0.346666667 
SD 0.001732051 0.0005 0.02081666  SD 0.001732051 0.003356089 0.011547005 
 
 
  SWT  
 Ret. Time (Min) Peak Area (mAU*Min) Peak Height (mAU) 
 11.7 0.0119 0.11 
 11.7 0.0133 0.12 
 11.7 0.0132 0.12 
AV 11.7 0.0128 0.116666667 
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